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CHAPTER I 
 
 
INTRODUCTION 
 
 
 Feed is the most expensive cost in livestock production, being around 
70% of the total cost. Therefore, there is a need to provide a properly balanced 
diet, supplying the ideal amount of nutrients, allowing animals to demonstrate 
their maximum growth potential, and consequently, decreasing the cost of 
feeding and production.  
Corn is the main energy ingredient used in livestock production, especially 
for monogastrics. In the last 10 years, the price of corn has fluctuated as a 
consequence of diverse factors such as weather (drought), petroleum and 
gasoline price (cost of transportation), use of corn for ethanol production, and 
availability.  
As a result of the fluctuation in price and the occasional limited availability 
of corn, there is great concern in the poultry and swine industry about the quality 
of corn. One of the major concerns is related to the contamination of corn by 
fungi and the subsequent production of mycotoxins by the fungi. Mycotoxins are 
toxic secondary metabolites produced by organisms of the fungi kingdom, 
commonly known as molds. The term “mycotoxin” is usually reserved for the toxic 
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chemical products produced by fungi that readily colonize crops, and that are not 
directly essential for growth of the fungi. One fungal species may produce many 
different mycotoxins, and the same mycotoxin may be produced by several 
species of fungi (Turner et al., 2009; Richard, 2007). The most common fungi 
species found in corn are Aspergillus flavus and A. parasiticus (produce 
aflatoxins); Fusarium moniliforme and F. proliferatum (produces fumonisins); 
Fusarium graminearum (produces xearalenone and deoxynivalenol, also known 
as DON or vomitoxin); F. culmorum, F graminearum, and  F. poae (produces the 
trichothecenes), and; Penicillium verrucossum and Aspergillus ochraceus 
(produces ochratoxins). Mycotoxins are known to cause serious health problems 
in animals including equine leukoencephalomalacia, porcine pulmonary edema, 
and liver necrosis in poultry. Reduced weight gain, capillary fragility, reduced 
fertility, suppressed disease resistance, and even death have been attributed to 
mycotoxins. No animal is known to be resistant, but in general, older animals are 
more tolerant than younger animals (Koenning and Payne, 2000).  
Fungi are opportunist organisms. Once the kernel wall of grain is 
damaged, due to drought stress or insect damage, the specific fungus will invade 
the kernel and under the right conditions, produces its specific mycotoxin. 
Mycotoxin production in the kernel is not the only problem. Fungi also need 
nutrients to develop, thus the fungus will also decrease nutrients available to the 
animal, and consequently decrease animal performance. 
The main mycotoxin found in poultry and swine feed is aflatoxin B1 (AFB1) 
which is mainly produced by Aspergillus flavus and A. parasiticus. AFB1 is the 
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most potent naturally occurring chemical liver carcinogen known. These fungi 
can colonize crops in tropical and subtropical regions worldwide, or can also 
produce aflatoxin in storage, transportation, and during food processing (Wu and 
Guclu, 2012). Aflatoxicosis (toxic effects of aflatoxin) in animals can be acute 
and/or chronic. Acute cases are characterized by severe liver damage, whereas 
liver cirrhosis, liver cancer and DNA damage occur in chronic toxicity. Chronic 
intake of AFB1 in animals can lead to low feed intake and weight gain. The 
effects caused by aflatoxin consumption is mostly chronic due to the low 
exposure for a long period, which in some cases are not detected by the 
producer. A brief exposure to high concentrations of aflatoxins however, may 
produce a wide range of acute effects that vary with species, age, sex, nutritional 
status, and the dose (Patnaik, 2007). 
In industrial nations, aflatoxin contamination of food and feed primarily 
causes economic rather than health burdens. It reduces the price paid for crops, 
and can cause disposal of large amounts of food. Losses from aflatoxin in the US 
– in the hundreds of millions USD annually – are associated with market loss 
rather than health effects, as enforcement of aflatoxin standards and aflatoxin 
control methods have largely eliminated harmful exposure in food (Wu, 2004). 
Mycotoxins have significant economic impacts on numerous crops, especially 
wheat, maize, peanuts and other nut crops, cottonseed, and coffee. The Food 
and Agriculture Organization has estimated that 25% of the world’s crops are 
affected by mycotoxins each year, with annual losses of around 1 billion metric 
tons of foods and food products (FDA, 2009). Economic losses occur because of: 
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1) yield loss due to diseases induced by toxigenic fungi; 2) reduced crop value 
resulting from mycotoxin contamination; 3) losses in animal productivity from 
mycotoxin-related health problems; and 4) human health costs. Additional costs 
associated with mycotoxins include the cost of management at all levels– 
prevention, sampling, mitigation, litigation, and research costs. These economic 
impacts are felt all along the food and feed supply chains affecting crop 
producers, animal producers, grain handlers and distributors, processors, 
consumers, and society as a whole (due to health care impacts and productivity 
losses). Estimates of the costs of mycotoxins in the United States vary: one 
report estimated $0.5 to $1.5 billion/yr and another estimated $5 billion/yr for the 
U.S. and Canada. Aflatoxins in maize in the U.S. have been estimated to have a 
$225 million/yr impact, excluding mitigation costs which is around $20 to 30 
million/yr just for testing (Schmale III, 2013). 
As maize is increasingly used to produce ethanol, the economic impact of 
mycotoxins will not decrease, and may actually increase. An important co-
product of ethanol production is dried distillers’ grain with solubles (DDGS), 
which is sold as an animal feed ingredient. Mycotoxins in the original grain 
become concentrated in the DDGS, resulting in an estimated $18 million impact 
per year for fumonisins in the U.S. swine industry. Losses to the swine industry 
may be lower because of grain monitoring by ethanol plants; in this case the 
economic impact of fumonisins in DDGS would be spread out among the swine 
industry, the ethanol industry, and maize producers. In order to maintain 
acceptable mycotoxin levels in DDGS, incoming grain should be strictly 
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monitored, but this will certainly lead to higher costs for the ethanol plant and a 
loss of salability of mycotoxin-contaminated grain (Schmale III, 2013). 
 
The objectives of these studies are: 
- To identify genes whose expression are modified in response to aflatoxin 
B1, and to identify pathways that control growth, development, 
coagulation, immune function, metabolism, detoxification, and antioxidant 
status of weanling pigs and young turkeys. 
- To determine if turmeric powder (TMP) containing curcuminoids would be 
able to prevent or reduce the negative effects associated with oxidative 
stress and increase performance in young turkey poults fed AF. 
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
 
Mycotoxins: 
Mycotoxins are toxic secondary metabolites produced by organisms of 
the fungi kingdom, commonly known as fungi. The term 'mycotoxin' is usually 
reserved for the toxic chemical products produced by fungi that readily colonize 
crops, and are not directly essential for growth of the fungi. One fungi species 
may produce many different mycotoxins, and the same mycotoxin may be 
produced by several species of fungi (Turner et al., 2009; Richard, 2007). 
Fungal growth and mycotoxin production are related to weather extremes 
(causing plant stress or excess hydration of stored feedstuffs), inadequate 
storage practices, low feedstuff quality, and poor feeding conditions.  In general, 
environmental conditions (such as heat, water, and insect damage) may cause 
plant stress and predispose plants in the field to fungal contamination and in turn 
to mycotoxin production.  Because feedstuffs can be contaminated post-harvest, 
control of additional fungi growth and mycotoxin formation is dependent on 
storage management.  After harvest, temperature, moisture content, and insect 
activity are the major factors influencing fungal contamination and mycotoxin 
production in feed grains and foods. One fungal (or mold) species may produce 
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many different mycotoxins and/or the same mycotoxin as another species 
(Robbins et al., 2000). There are hundreds of mycotoxins known, but few have 
been extensively researched and even fewer have good methods of analysis 
available. 
According to Fox and Howlett (2008) and many other authors, the reason 
for the production of mycotoxins is not yet known. They are necessary neither for 
growth nor development of the fungi. Because mycotoxins weaken the host, the 
fungus may use them as a strategy to better the environment for further fungal 
proliferation. The production of toxins depends on the surrounding intrinsic and 
extrinsic environments, and the toxins vary greatly in their toxicity, depending on 
the organism infected and its susceptibility, metabolism, and defense 
mechanisms. Some mycotoxins are harmful to other micro-organisms such as 
other fungi and bacteria (Hussein and Brasel, 2001; Keller et al., 2005). 
The production of these secondary metabolites by fungi is still a mystery, 
but there are a few theories about why fungi produce mycotoxins. The first theory 
is called “Protection of the fungus”. Since mycotoxins are toxic, or at least, cause 
some metabolic and health problems (suppression of immunity, cellular death, 
allergens or irritants, etc.) for those exposed to the feedstuff containing a specific 
mycotoxin, this could be used as defense mechanism to protect the fungus and 
ensure its survival. The second theory is called “Assist the fungus in creating an 
environment for survival and growth”. Mycotoxins may prevent the attack, of 
animal and other live organisms on the fungus, which will benefit the fungus’ 
survival. In general, fungi need an optimum temperature and humidity to develop 
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and grow (for example, Aspergillus flavus and Aspergillus parasiticus, the two 
fungi that produce aflatoxin, need 14% or higher humidity and a temperature of 
25oC (80oF) or higher to develop and grow). If the conditions are not ideal for the 
fungal development, the fungus will not grow and, consequently there will be no 
mycotoxin production. 
There are studies in the literature that used phylogenetic analysis on the 
evolution of some fungal species and their mycotoxin production. In one of these 
studies, the only conclusion reached was that phylogenetically unrelated species 
were found to produce the same mycotoxin where genes of several pathways 
(described as having disposable metabolic functions) are also clustered in the 
genome and could be horizontally transferred as a unit to unrelated species, 
leading to the biosynthesis of the same mycotoxins (Varga, et al., 2003). 
In summary, mycotoxins may provide fitness benefits in terms of 
physiological adaptation, competition with other microbes and fungi, and 
protection from consumption (Demain and Fang, 2000; Rohlfs et al., 2007).  
 
Aflatoxin: 
Aflatoxins are toxic secondary metabolites produced by many species of 
Aspergillus, with the most notable being Aspergillus flavus and Aspergillus 
parasiticus. At least 14 different types of aflatoxin are produced in 
nature. Aflatoxins are chemically difuranocoumarins and the most prevalent 
found in the field are B1, B2, G1, and G2, but M1 and M2 can also be found in milk 
(Figure 2.1). Aflatoxins “1” (AFB1 and AFG1) are considered more toxic than “2” 
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(AFB2 and AFG2) due to the 8 and 9 double bond present in their chemical 
structure, where epoxidation can occur. Aflatoxin B1 is considered the most toxic 
and is produced by both Aspergillus flavus and Aspergillus parasiticus. While the 
presence of Aspergillus sp in food products does not always indicate that 
aflatoxins are also present, it does imply a significant risk in consumption of the 
food produced. Aflatoxins M1 and M2 were originally discovered in the milk of 
cows fed moldy grain containing AFB1 and AFB2, but AFM1 was also reported, in 
small quantities, in eggs (Yunus et al, 2011). These compounds are products of a 
bioconversion process in the animal's liver. However, aflatoxin M1 is also present 
in the fermentation broth containing Aspergillus parasiticus (Boutrif, 1998). 
Aflatoxin B1 is a carcinogenic toxin and the main target organ is the liver 
(hepatotoxic). High-level aflatoxin exposure produces an acute hepatic necrosis, 
resulting in cirrhosis, and/or carcinoma of the liver. Acute hepatic failure is made 
manifested by hemorrhage, edema, alteration in digestion, changes in the 
absorption and/or metabolism of nutrients, and mental changes and/or coma 
(Marin et al., 2002). Chronic, subclinical exposure does not lead to symptoms as 
dramatic as acute aflatoxicosis, however it leads to a high risk of developing liver 
cancer, as aflatoxin metabolites can intercalate into DNA and alkylate the bases 
through its epoxide moiety (Bedard and Massey, 2006). This is thought to cause 
mutations in the p53 gene, an important gene in preventing cell cycle 
progression when there are DNA mutations, or signaling apoptosis (Aguilar et al., 
1993). Covalent binding to DNA is generally a property of those specific 
aflatoxins containing an unsaturated terminal furan ring forming an epoxide. 
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Despite the uncertainties about the specific role of individual human cytochrome 
P450s in the metabolism of aflatoxin to its two 8,9-epoxide isomers, there is no 
doubt that this is the critical metabolite for genotoxic damage (Wang and 
Groopman, 1999).  
The Food and Drug Administration (FDA, 2013) has established the 
following action levels for aflatoxins present in animal feed and feed ingredients:  
- 20 parts per billion (ppb.) - For corn, peanut products, cottonseed meal and 
other animal feeds and feed ingredients intended for dairy animals; 
- 20 ppb - For corn, peanut products and other animal feeds and feed 
ingredients, but excluding cottonseed meal, intended for immature animals; 
- 100 ppb - For corn and peanut products intended for breeding beef cattle, 
breeding swine or mature poultry (e.g., laying hens); 
- 200 ppb – For corn and peanut products intended for finishing swine (100 
pounds (45.5 kg) or more); 
- 300 ppb – For cottonseed meal intended for beef cattle, swine or poultry 
(regardless of age or breeding status); and, 
- 300 ppb - For corn and peanut products intended for finishing beef cattle 
(e.g., feedlot cattle). 
  Marin et al. (2002) demonstrated that subclinical exposure of young swine 
to AFB1 (140 ppb and 280 ppb) in the diet is associated with a number of effects 
manifested by a reduction in weight gain, changes in several blood parameters, 
and alteration of both humoral and cellular immune responses. Rauber et al 
(2007) demonstrated that the presence of aflatoxins in doses equal to or higher 
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than 200 ppb negatively affected turkey performance during the period evaluated 
(1 to 42 d). The authors also reported that turkey poults are very sensitive to 
aflatoxin, because they are at least three to six times more sensitive to these 
contaminants than broilers. Highly sensitive species such as turkeys and ducks 
produce large amounts of AFBO (aflatoxin-8-9-exo-epoxide) compared to less 
sensitive species such as chickens and quail. However, no studies were 
conducted to determine the specific cytochrome (CYP) enzymes responsible for 
this bio-activation reaction. The identification of these enzymes could potentially 
have important implications for poultry production since their expression could be 
manipulated through the use of enzyme inhibitors or genetic selection (Diaz et 
al., 2010). 
 
Aflatoxin in poultry:  
 Aflatoxin is a great concern for the poultry industry because it is found in 
corn, which is the main ingredient of poultry rations. Several studies have been 
conducted in poultry species to determine tolerant levels of aflatoxin among the 
species, and to verify the toxic effects of aflatoxin. Gumbmann et al. (1970) 
conducted an experiment feeding 800 ppb aflatoxin to various poultry species 
including strain, crosses, or breeds of chicken, turkey and quail. They determined 
that one of the most sensitive biochemical responses to aflatoxin intoxication was 
a decrease in plasma albumin, and reduction in liver succinic dehydrogenase 
and nucleic acid concentration, being more evident in turkey poults. 
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Turkey poults are very sensitive to aflatoxin poisoning, and economic 
losses can occur during industrial production. Rauber et al. (2007) concluded that 
aflatoxin doses equal or higher than 200 ppb negatively affected turkey 
performance, with higher doses showing statistical differences in BW, feed 
conversion, relative weight of liver, mortality, and total protein and cholesterol 
levels in serum. Based on their results, the same authors concluded that turkey 
poults are three to six times more sensitive to aflatoxin than broilers. Santurio et 
al. (1998), in a study feeding increasing level of AFB1 (up to 2,000 ppb) to turkey 
poults demonstrated decreased performance with increasing levels of AFB1. 
The greater sensitivity of turkeys to AFB1 was first demonstrated in 1960. 
The discovery and isolation of aflatoxins was a result of investigations on the 
mysterious Turkey – X disease of 1960 which caused massive mortality of 
turkeys and other poultry species in Europe (Stevens et al., 1960). The 
suspected toxic factor was found to be extractable from Brazilian peanut meal by 
using chloroform and, its association with Aspergillus flavus, was established in 
the year 1961 (Blount, 1961). In 1962, the name “aflatoxin” was proposed using 
the first letter from “Aspergillus” and the first three letters of “flavus”. Turkeys are 
extremely sensitive to AFB1. According to Rawal (2010), the extreme sensitivity 
of turkeys to AFB1 is associated with efficient hepatic cytochrome P450-mediated 
bioactivation and inefficient detoxification by glutathione S-transferase (GST). 
Broilers are less sensitive to aflatoxins than turkeys but several studies 
have been conducted to demonstrate the toxics effects of aflatoxin in broilers. 
Gowda et al. (2008) demonstrated that broilers fed 1 mg/kg of AFB1 for 21 days 
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significantly lower feed intake, and weight gain, and increased relative liver 
weight. Marchioro et al. (2013) reported that when broilers were fed up to 2.8 mg 
of AFB1/kg, there was a negative effect on all performance parameters. Also, 
pancreatic activity of lipase and α-amylase were significantly increased, affecting 
the digestibility of the diet, thus leading to losses in performance and productivity. 
In an experiment feeding corn naturally contaminated with AFB1 and AFB2, Yang 
et al. (2012) observed that broilers fed AF contaminated diets were negatively 
affected leading to induction of pathological lesions in the liver. 
The consumption of feed contaminated with AFB1 can affect digestive 
enzyme activities, nutrient digestibility and utilization, leading to poor animal 
performance. Aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) are serum enzymes and the increased activity of these enzymes can be 
used as a tool to indicate abnormal liver activities caused by AFB1 (Han et al., 
2008). Also, it is believed that aflatoxicosis results in reduced activity of several 
digestive enzymes such as amylase, trypsin, chymotrypsin and lipase, resulting 
in malabsorption of nutrients in the small intestine. Marchioro et al. (2013) 
observed an increased pancreatic activity of lipase and α-amylase in birds fed 
1.7 and 2.8 mg AF/kg diet, while the specific activity of trypsin was only 
negatively affected when birds were fed 2.8 mg AF/kg diet. 
Aflatoxin can also affect bone mineralization, which can induce or 
aggravate skeletal problems due to the reduction of reabsorption of calcium (Ca) 
and phosphorus (P) in the kidneys (Resanoviã et al., 2009). According to 
Waldenstedt (2006), aflatoxin and ochratoxin both decrease bone strength due to 
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an interference with Vitamin D metabolism, leading to deficiency of Vitamin D3. 
Scheideler (1993) observed that bone ash levels of broilers fed 2.5 mg AF/kg diet 
were significantly lower compared to control. Jewers (1990) stated that 
aflatoxicosis results in a rubbery condition of the bones apparently related to 
increased tibial diameters and perhaps poor mineralization of bone tissue in 
young broiler chicks. 
Serum biochemical and hematological parameters are two analyses that 
can indicate and diagnose in toxication with aflatoxin (Huff et al., 1986). Changes 
in serum concentration of total protein, albumin, total cholesterol, uric acid, 
calcium and phosphorus could be a indication of aflatoxin toxication (Rosa et al., 
2001; Oguz and Kurtoglu., 2000). Basmacioglu et al. (2005) fed diets containing 
2 mg AFB1/kg diet to broilers and observed a decrease in serum total protein, 
albumin, total cholesterol, triglyceride, glucose, inorganic phosphorus, creatinine 
levels, ALT activity, red blood cell, hemotocrit, and hemoglobin but an increase in 
AST activity. Rauben et al. (2007) observed a significant reduction in total serum 
protein and serum cholesterol of broilers fed 500 and 1,000 ppb AF for 21 days.  
Yunus et al. (2011) reviewed studies of aflatoxin B1 affecting broiler 
performance, immunity, and gastrointestinal tract (GIT) characteristics published 
in the last decade. The authors observed that as the level of AFB1 increased to 1 
mg/kg, total serum protein and albumin contents were decreased and, at higher 
levels of 2 mg AFB1/kg diet, serum glucose, Ca, and inorganic P levels were 
decreased. They also observed altered concentration of digestive enzymes in 
broilers fed > 1 mg AFB1/kg feed. 
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Aflatoxin in swine: 
 Corn is the main energy ingredient of pig diets. Aflatoxins is a big concern 
for the swine industry especially because Aspergillus sp. is a common 
contaminant in corn. The effect of feeding diets containing aflatoxins to pigs 
depends on several factors such as age and health of pig, concentration of the 
toxin, and duration of exposure. Pigs are highly susceptible to aflatoxin, 
especially in the weaning stage as AF can cause a variety of chronic or acute 
syndromes depending on the level of concentration and consumption of diets 
contaminated with AF (Lawlor and Lynch, 2001). Short-term, low-level exposure 
may have minimal effects such as reduction of feed intake and immune 
suppression. However, feeding aflatoxins at high levels (acute) or for long time 
periods (chronic) can cause the toxin to build up in body tissues, impairing the 
immune system (immune suppression), decreasing performance, reducing 
reproductive capability, and in more extreme cases, causing mortality. Dilkin et 
al. (2003), fed low levels of AFB1 (50 µg AFB1/kg) , fumonisin B1 (30 µg FB1/kg), 
and a combination of both for 28 days, and observed signs of pulmonary edema, 
reduced feed consumption and body weight gain, and increased cholesterol 
levels and albumin concentration.  
The maximum tolerable levels of aflatoxin in pig diets (FDA, 2013) are: 
- Nursery pigs (less than 50 lbs/ 22.7 kg): < 20 ppb; 
- Gestating and lactating sows: < 100 ppb; 
- Growing-finishing pigs: < 200 ppb, and; 
- Late finishing pigs: < 20 ppb. 
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In pigs, AF decreases the blastogenesis response to mitogens, reduces 
complement titers, decreases macrophage activation, and depresses delayed 
hypersensitivity (Marin et al., 2002). Panangala et al. (1986) observed reduction 
of complement titers and an increase in serum immunoglobulin G (IgM) and M 
(IgM) in pigs fed 500 µg AFB1/kg diet. Meissonnier et al. (2008) observed 
impaired cell-mediated immunity while inducing an inflammatory response (up-
regulation of cytokines such asTNF-α, IL-1β, IL-6, IFN-γ, and IL-10) in pigs fed 
1807 µg pure AFB1/kg feed.  
Pigs consuming AF had increased serum activities of alkaline phosphatase, 
aspartate transaminase, cholinesterase and γ-glutamyltransferase, and 
decreased serum concentrations of urea nitrogen, cholesterol, albumin, total 
protein, calcium, potassium, magnesium and phosphorus (Harvey et al., 1990). 
The pathological effects of aflatoxin include liver damage characterized by 
enlargement, release of enzymes into the blood (e.g., aspartate 
aminotransferase, y-glutamyltransferase, and alkaline phosphatase), and 
impaired protein synthesis (Schell et al., 1993). Increased serum glutamic-
oxaloacetic transaminase, alkaline phosphatase, and isocitric dehydrogenase, 
and decreased plasma albumin, albumin:globulin ratio, nonprotein nitrogen, urea 
nitrogen, vitamin A and glycogen were observed when pigs were fed 810 ppb of 
aflatoxin (Gumbmann and Williams, 1969). Chaytor et al. (2011) observed that 
combination of 120 ppb aflatoxin and 600 ppb deoxynivalenol (DON) resulted in 
altered immune health, systemic inflammation, and partial liver damage, causing 
further reduction in growth of pigs. 
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Aflatoxins, which are also carcinogenic, can be transmitted from lactating 
sows to nursing pigs via the milk, consequently contaminating the piglets (The 
pig site, 2013). Crenshaw (2008) reported the presence of aflatoxin M1 (AFM1) in 
the milk of nursing sows consuming diets containing 500 and 750 ppb of AFB1. 
The author also reported that pigs consuming milk containing AFM1 had a higher 
death rate, slower growth which also had an impact in the growing/finishing 
period. Weaver (2013) reported that the concentration of AFM1 was 1.5 to 1.9 
times higher in colostrum than milk of nursing sows. According to Barbiroli et al. 
(2007), AFM1 is likely to be linked to the milk protein (casein), where more than 
80% of total AFM1 can be bound to the protein and transferred to the piglets. 
Aflatoxin is not deposited to a great extent in the tissues and the toxic 
effects are quickly diminished as soon as the aflatoxin source is removed. 
Southern and Clawson (1979) fed 20, 385, 750, and 1,480 ppb AFB1 to pigs for 
66 days. On day 66, one-half of the pigs were used in a short (7-days) withdrawal 
trial. The pigs placed on control diets consumed more feed, had faster gain and 
were more efficient than the pigs that remained on their respective aflatoxin-
contaminated diet (Schell et al., 1993). Gross enlargement of the liver, 
substantiated by histologic evidence of toxic damage to the hepatic parenchyma, 
revealed that AF at concentrations of 500 mg/kg of feed was toxigenic and 
produced an adverse effect on the growth rate, feed efficiency, and general well-
being of young pigs (Panangala et al., 1986). 
Pigs are one of the most sensitive livestock species to aflatoxin. The 
mechanism of action of aflatoxin which make pigs very sensitive is not well 
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known and there are just a few studies trying to understand and explain this high 
sensitivity. There are two hypothesis that have been used to explain the 
sensitivity of pigs to aflatoxin. The first is that their higher level of sensitivity could 
possibly be an inability of the animal to appropriately detoxify aflatoxin.  
According to Gelven (2001), the second hypothesis is an increased ability of the 
animal to metabolize aflatoxin into its carcinogenic form (8, 9-epoxide), and 
perhaps decreased ability to detoxify aflatoxin. 
 
Antioxidants: 
Oxidation is a chemical reaction that results in the loss of electrons from a 
substance to an oxidant agent. Oxidation can result in the production of free 
radicals. Free radicals are atoms, molecules or ions with unpaired electrons, 
which are highly reactive to other molecules. These free radicals belong to a 
group of molecules called reactive oxygen species (ROS) (Lu et al., 2010). 
Oxidant damage in cells is caused by oxidative stress. Oxidative 
stress represents an imbalance between the production and manifestation 
of reactive oxygen species and a biological system's ability to readily detoxify the 
reactive intermediates or to repair the resulting damage. Disturbances in the 
normal redox state of tissues can cause toxic effects through the production 
of peroxides and free radicals that damage all components of the cell, 
including proteins, lipids, and DNA. Some reactive oxidative species can even 
act as messengers in redox signaling (Schafer and Buettner, 2001). Chemically, 
oxidative stress is associated with increased production of oxidizing species or a 
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significant decrease in the effectiveness of antioxidant defenses, such 
as glutathione. The effects of oxidative stress depend upon the size of these 
changes, with a cell being able to overcome small perturbations and regain its 
original state. However, more severe oxidative stress can cause cell death and 
even moderate oxidation can trigger apoptosis, while more intense stresses may 
cause necrosis (Lennon et al., 1991). Production of reactive oxygen species is a 
particularly destructive aspect of oxidative stress. Such species include free 
radicals and peroxides. Some of the less reactive of these species (such 
as superoxide) can be converted by oxidoreduction reactions with transition 
metals or other redox cycling compounds (including quinones) into more 
aggressive radical species that can cause extensive cellular damage (Valko et 
al., 2005). The major portion of long term effects is inflicted by damage to DNA 
(Evans and Cooke, 2004). Most of these oxygen-derived species are produced at 
a low level by normal aerobic metabolism. Normal cellular defense mechanisms 
destroy most of these. Likewise, any damage to cells is constantly repaired. 
However, under the high levels of oxidative stress that cause necrosis, the 
damage causes ATP depletion, and causing the cell to simply fall apart (Lelli et 
al., 1998). 
Antioxidants are molecules or enzymes that inhibit the oxidation of other 
molecules. Antioxidant enzymes like  superoxide dismutase (SOD) and 
glutathione peroxidase (GPx) form the first line of defense against ROS and a 
decrease in their activities was observed with AFB1 administration (Verma and 
Nair, 2001). Superoxide dismutase protects cells from oxidative damage by 
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breaking down a potentially hazardous free radical superoxide (O2 .−) to 
hydrogen peroxide (H2O2) and oxygen (O2) (Venkateswaran, et al., 1987). The 
function of GPx is to remove the H2O2 generated by metabolic action or oxidative 
stress. The activity of GPx is highly dependent on glutathione (GSH) 
concentration (Meister and Anderson, 1991). Glutathione, the major thiol 
antioxidant, is a multifunctional intracellular nonenzymatic antioxidant (Masella, 
et al., 2005). Glutathione can inhibit peroxidation, scavenge free radicals, and 
protect cell membranes (Patel, 1987). Thus, significantly lower GSH levels would 
further aggravate the toxic effects of aflatoxin (Verma, 2004). Glutathione can 
scavenge peroxynitrite and OH· as well as convert H2O2 to water with the help of 
GPx (Venkataraman, et al., 2004). 
Several chemical compounds and antibiotics, which play a key role in 
human and animal health, have been identified in herbaceous plants by 
researchers. The medicinal plant turmeric (Curcuma longa) is commonly used as 
a spice in human food. Turmeric is a rhizomatous herbaceous perennial plant of 
the ginger family. Turmeric contains up to 5% essential oils and up to 5% 
curcuminoids polyphenols. The active ingredients found in turmeric are curcumin, 
demethoxycurcumin, and tetrahydrocurcuminoids (Wuthi-Udomler et al., 2000; 
Osawa et al., 1995). Turmeric and its active substance, curcumin, have been 
shown to have antifungal and anti-oxidative value, nematocidal and anti-
inflamatory activities (Soni et al., 1997). Moreover, turmeric, as a food additive, 
has been shown to have protective effects against aflatoxin-induced mutagenicity 
and hepatocarcinogenicity (Durrani, et al., 2006).  
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The curcuminoids, yellowish pigments present in turmeric powder, have 
been shown to have protective effects against AFB1.  Supplementation of 
curcumin in the diet normalized the altered activities of LDH and ALT induced by 
AF. At a molecular level, curcumin significantly reduced AFB1 -N (7)-guanine 
adduct excretion in the urine, DNA adducts in the liver, and albumin adducts in 
the serum of male rats (Nayak and Sashidhar, 2010). Yarru et al. (2009a) 
demonstrated that the supplementation of turmeric powder in diets containing 
AF, improved expression of antioxidant, biotransformation, and immune system 
genes of broiler chicks. 
Several authors have recently focused on the inhibition of aflatoxin 
biotransformation to its 8,9-epoxide constituents through interaction with 
cytochrome P450 enzymes using oltipraze (Kuilman et al., 2000) or natural 
compounds (Kim et al., 2000). Curcumin has been shown to inhibit the 
biotransformation of AF to its active epoxide derivatives. The carbonyl functional 
group of the curcuminoids is thought to be responsible for their antimutagenic 
and anticarcinogenic action. Curcumin has a strong inhibitory effect on 
superoxide anion generation and biotransformation of AFB1 to aflatoxicol in the 
liver (Lee et al., 2001). Addition of turmeric powder (0.5%) containing 1.4% total 
curcuminoids to an AFB1 contaminated chick diet increased the activity of 
superoxide dismutase (SOD) and reduced the peroxide level in liver 
homogenates of broiler chicks (Gowda et al., 2008).  
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Aflatoxin and gene expression: 
 Aflatoxin B1 causes free radical production, lipid peroxidation, and cell 
damage (Surai, 2002). There is very little research in the literature related to 
aflatoxin B1 and its impact on gene expression. There are some mechanisms 
already known on how aflatoxin can cause cell and DNA damage. 
Aflatoxin B1, once ingested by the animal, is oxidized by cytochrome P450 
enzymes, producing the 8,9-exo-epoxide, which will bind to DNA. 
Biotransformation plays a crucial role in the disposition, toxicity, and 
carcinogenicity of AFB1. Toxic and carcinogenic effects are attributable to the 
action of metabolites that are capable of reacting with cellular macromolecules 
(Eaton et al., 1994). Aflatoxin B1, as mentioned before, is bioactivated by 
epoxidation of the terminal furan ring double bond, generating the electrophilic 
intermediate AFB1-8,9-epoxide, a stereoisomer which can exist in both the exo 
and endo conformation (Figure 2.2). Aflatoxin B1-endo-epoxide is very weakly 
mutagenic. In contrast, AFB1-exo-epoxide is capable of alkylating nucleic acids 
and proteins (Bedard and Massey, 2006). 
The reactivity of AFB1-exo-epoxide and DNA is at least 1000-fold greater 
than that of the endo isomer (Iyer et al., 1994). The most plausible explanation 
for this difference in reactivity is the intercalation of the furanocoumarin entity of 
the epoxide between the base in DNA orienting the epoxide for SN2 attack by N7 
of guanine, forming trans-8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-
N7-Gua)  as the primary AFB1-DNA adduct (Bedard and Massey, 2006). Only 
very low levels of adducts are formed upon reaction of AFB1 –endo-epoxide with 
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DNA because nucleophilic attack by guanine N7 is blocked by the oxirane ring of 
the endo-epoxide upon its intercalation into DNA (Iyer et al., 1994). 
The traditional view has been that DNA alkylation by AFB1-exo-epoxide 
and subsequent AFB1-N7-Gua formation results in G to T transversion, the most 
frequently observed mutation induced by AFB1. However, 8-OHdG (8-Oxo-2’-
deoxyguanosine) also produces predominantly G to T transversion mutations 
(Cheng et al., 1992), consistent with the possibility that AFB1-induced oxidative 
DNA damage contributes to AFB1 carcinogenesis. While many reactive oxygen 
species such as the superoxide radical anion, hydrogen peroxide and lipid 
hydroperoxides do not appear to interact with DNA, they are precursors to the 
hydroxyl radical. The reaction of the hydroxyl radical with DNA generates a 
multitude of products since it attacks sugars, pyrimidines and purines, including 
guanine residues to form 8-OHdG (Halliwell and Gutteridge, 1999). 
Yarru et al. (2009a) fed 2 mg/kg AFB1 to broiler chicks for 21 days and 
observed down regulation of the expression of several genes associated with 
energy production and fatty acid metabolism (carnitine palmitoyl transferase), 
growth and development (glutathione S transferase), detoxification (epoxide 
hydrolase), coagulation (coagulation factors Ix and X), the immune system 
(interleukins), and up regulation of genes associated with cell proliferation 
(ornithine decarboxylase). Rustemeyer et al. (2011) demonstrated that the 
administration of 250 and 500 µg/kg of AFB1 in the diet of pigs for 40 days 
caused alterations in hepatic genes associated with apoptosis, such as cyclin-
dependent kinase inhibitor 1A, zinc finger matrin type 3, kininogen 1, pim-1 
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oncogene, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, zeta polypeptide; and apoptosis enhancing nuclease. Yarru et al. 
(2009b) concluded that the inclusion of 0.5% food-grade turmeric powder (TMP) 
that supplied 74 mg total curcuminoids/kg diet improved bird performance and 
prevented the negative effects of aflatoxin on the expression of genes associated 
with antioxidant (SOD and Glutathione S-transferase - GSTα), immune (interlekin 
6 – IL-6), and detoxification (CYP1A1, CYP2H1, and epoxide hydrolase - EH) 
mechanisms in liver of chicks fed 1.0 mg of AFB1/kg of diet. 
 
Excretion of aflatoxin: 
Aflatoxins are highly liposoluble compounds and are readily absorbed 
from the site of exposure usually through the gastrointestinal tract and respiratory 
tract into the blood stream. They are distributed in blood to different tissues and 
to the liver, the main organ of metabolism of xenobiotics. Aflatoxin is not 
accumulated to a great extent in any tissue, being readily cleared after the toxin 
is removed from feed. Aflatoxin excretion is via bile, urine, feces, milk and eggs. 
The biotransformation of AFB1 is important for its excretion. In general, the 
metabolism or biotransformation of xenobiotics (chemicals foreign to the 
organism) is a process aimed at converting the original molecules into more 
hydrophilic compounds readily excreted in the urine (by the kidney) or in the bile 
(by the liver). It has traditionally been conceptualized that this process occurs in 
two phases known as Phase I and Phase II, although some authors argue that 
this classification is no longer tenable and should be eliminated (Josephy et al., 
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2005). Phase I metabolism (Figure 2.1) consists mainly of enzyme-mediated 
hydrolysis, reduction and oxidation reactions, while Phase II metabolism (Figure 
2.3)  involves conjugation reactions of the original compound or the compound 
modified by a previous Phase I reaction (Diaz and Murcia, 2011). 
 Cytochromes P450 (CYP450) are enzymes responsible for most oxidation 
of AFB1 in Phase I reactions, but one reaction is catalyzed by a cytosolic 
reductase, corresponding to the reduction of AFB1 to aflatoxicol (AFL). Phase II 
reactions are limited to conjugation of the metabolite AFB1-exo-8,9-epoxide 
(AFBO) with glutathione (GSH, y-glutamyl-cysteinyl-glycine), and conjugation of 
aflatoxins P1 and M1-P1 with glucuronic acid. Conjugation of AFBO with GSH is a 
nucleophilic trapping process catalyzed by specific glutathione transferase (GST) 
enzymes. The AFBO may also be hydrolyzed by an epoxide hydrolase (EPHX) to 
form AFB1-exo-8,9-dihydrodiol, although this reaction may also occur 
spontaneously. The dihydrodiol is in equilibrium with the dialdehyde phenolate 
form, which can be reduced by AFB1 aldehyde reductase (AFAR), an enzyme 
that catalyzes the NADPH-dependent reduction of the dialdehyde to dialcohol 
phenolate (Guengerich et al., 2001).  
The translocation of xenobiotics across cell membranes (anti-porter 
activity) by specific proteins known as transporters has been called “Phase III” 
metabolism (Figure 2.4). However, this process does not involve any modification 
of the xenobiotic structure and therefore it cannot be called metabolism. This is 
an energy-dependent efflux pump, which pumps xenobiotics out of a cell, thereby 
decreasing the intracellular concentration of xenobiotics. This process, however, 
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may have important implications on the toxic effect of a xenobiotic, particularly if 
the specific transporter involved in the translocation of the compound is not 
expressed normally, presents a genetic abnormality, or becomes saturated (Diaz 
and Murcia, 2011).  
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Figure 2.1 - Chemical structure of aflatoxins  
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Figure 2.2 – AFB1-induced DNA damage. 
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Figure 2.3 – Phase I and II Metabolism: Liver detoxification 
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Figure 2.4 – Phase III Metabolism: The antiporter activity. 
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CHAPTER III 
 
EFFECTS OF AFLATOXIN B1 (AFB1) AND CURCUMIN ON HEPATIC GENE 
EXPRESSION IN WEANLING PIGS 
 
 
ABSTRACT 
 
 
 The objective of the present study was to evaluate the efficacy of 
curcumin (CMN), an antioxidant supplied by turmeric (Curcuma longa) powder to 
ameliorate the adverse effects of aflatoxin B1 (AFB1) on performance of pigs and, 
to identify changes in gene expression in liver of pigs fed aflatoxin (AF). Twenty 
crossbred weanling pigs were weighed, ear-tagged, and assigned to each of four 
dietary treatments, which included: 1) basal diet (BD) containing no AFB1 or 
CMN;  2) BD + 1.0 mg AFB1/kg of diet;  3) BD + 100 mg curcumin (CMN)/kg of 
diet, and; 4) BD + 100 mg CMN/kg of diet + 1.0 mg AFB1/kg of diet. Aflatoxin 
reduced (P < 0.05) body weight gain (BWG), feed intake (FI) and feed efficiency 
of pigs. The addition of CMN to the diet contaminated with AFB1 improved feed 
efficiency (P < 0.05) but not BWG and FI. At the end of three week treatment 
period, livers were collected and microarray analysis was conducted to identify 
pathways that control growth, development, coagulation, immune function, 
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metabolism, detoxification, and antioxidant status in liver of pigs. Genes with an 
adjusted permutation Fs test (false discovery rates) values less that 5% and fold 
change greater than 2.0 were considered differentially expressed across 
treatments. Changes in expression were determined using microarray technique 
and results were validated using quantitative real time PCR (RT-qPCR). Six 
genes were chosen for validation of expression using RT-qPCR, including TNF 
receptor superfamily, member 6 (FAS), glutathione S-transferase theta 1 
(GSTT1), cyclin G1 (CCGN1), proteasome activator subunit 1 (PSME1), 
proteasome activator subunit 3 (PSME3), and cytochrome P450-2A19 
(CYP2A19). There were no differences in the expression of the genes among the 
treatments except for GSTT1 and CYP2A19 that shifted the expression (down to 
up, and up to down regulation, respectively) with the addition of CMN to the diet 
contaminated with AFB1. Results demonstrate that pigs fed 1.0 mg AFB1/kg feed 
for 21 days had reduced growth performance associated with altered hepatic 
gene expression, and the supplementation of 100 mg CMN/kg to diets containing 
AFB1 had a protective effect on changes in gene expression in liver of pigs. 
 
INTRODUCTION 
 
 Aflatoxins are a group of secondary metabolites produced by certain 
species of fungi. Aflatoxins are naturally occurring mycotoxins that are produced 
by many species of Aspergillus. Aflatoxins are toxic, and among the mycotoxins 
are the most carcinogenic substances known (Hudler, 1998). After entering the 
body, aflatoxins may be metabolized by the liver to a reactive epoxide 
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intermediate (e.g., AFB1-8,9-epoxide) or hydrolyzed, to the less harmful aflatoxin 
M1. AFB1-8,9-epoxide irreversibly binds to protein and DNA to form adducts, 
such as AFB1-lysine in albumin and a guanyl-N7 adduct in DNA, disrupting these 
proteins and DNA in hepatocytes (Skipper and Tannenbaum, 1990; Azziz-
Baumgartner et al., 2005). 
 Contamination of grains such as corn, peanut, and tree nuts with 
aflatoxins have been well documented. Among this group, aflatoxin B1 (AFB1) is 
the most potent naturally occurring genotoxic carcinogenic agent known (Eaton 
et al., 1994). In addition, AFB1 also shows potential immunotoxicity to peritoneal 
macrophages and splenic lymphocytes in certain animal species (Cusumano, 
1991; Neldon-Ortiz and Qureshi, 1991; Neldon-Ortiz and Qureshi, 1992). 
Pigs are not efficient in detoxifying and excreting aflatoxin, making them 
especially susceptible to aflatoxicosis. Susceptibility also varies with age, 
aflatoxin concentration, and duration of exposure. Regulatory limits for aflatoxin 
B1 in swine are < 20 parts per billion (ppb) for young pigs, < 100 ppb for breeding 
pigs, and < 200 ppb AFB1 for finishing pigs (FDA, 2009). The effects of aflatoxins 
in pigs include poor growth rate, poor feed conversion, increased mortality, 
increased susceptibility to bruising, impaired blood coagulation, impaired kidney 
function, altered immune response, increased susceptibility to diseases, and 
decreased ability to resist stress (Clarkson, 1980). 
The primary organ affected by aflatoxins is the liver. High dietary 
concentrations of aflatoxin (higher than 1,000 parts per billion) will result in acute 
problems such as hepatitis, necrosis of liver cells, prolonged blood clothing time, 
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and affected animals often die with severe hemorrhages. Sub-acute aflatoxicosis 
produces hepatic lipidosis, portal fibrosis, and proliferation of bile duct epithelium. 
Prolonged intake results in liver damage, depressed cell formation and hepatic 
tumors (Kendal, 1976). 
Lipid peroxidation plays a major role in aflatoxin toxicity. One alternative to 
ameliorate or protect against aflatoxicosis is the supplementation of feed with 
additives having antioxidant properties. According to Rastogi et al. (2001), 
supplementation of antioxidants could ameliorate the effects of aflatoxin B1 by 
preventing an increase in oxidation. 
Plant compounds such as coumarins, flavonoids, and curcuminoids are 
capable of inhibiting the biotransformation of AF to its epoxide metabolites 
(carcinogenic form of AF). The medicinal plant turmeric is commonly used as a 
spice in human food (Lee et al., 2001). Turmeric (Curcuma longa) powder has 
been used as an antioxidant supplement in AFB1 contaminated diets fed to 
poultry and swine. Curcumin (diferuloylmethane), a natural polyphenol, is the 
principle active ingredient of turmeric (Curcuma longa). It has been a popular 
spice in Asian and middle-eastern cuisines for centuries. The desirable 
preventive or putative therapeutic properties of curcumin have also been 
considered to be associated with its antioxidant and anti-inflammatory properties. 
Because free-radical-mediated peroxidation of membrane lipids and oxidative 
damage of DNA and proteins are believed to be associated with a variety of 
chronic pathological complications such as cancer, atherosclerosis, and 
neurodegenerative diseases, curcumin is thought to play a vital role against 
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these pathological conditions (Rajput et al., 2013). Gowda et al. (2008) 
demonstrated an improved antioxidant status and partial protection against the 
adverse effects of AFB1 when broiler chicks were fed diets containing 1.0 mg/kg 
AFB1 and 74 mg/kg of curcumin. Yarru, et al. (2009b) demonstrated partial 
protective effects of TMP on changes in expression of antioxidant, 
biotransformation, and immune system genes in liver of chicks fed AFB1. 
Identification of genes and pathways altered by dietary aflatoxins may lead 
to diagnostic, treatment, and prevention strategies for aflatoxicosis. Additionally, 
gene expression may provide a means of identifying animals more or less 
susceptible to aflatoxicosis, or differentiate the subtypes of aflatoxin causing 
toxicity, similar to the use of gene expression profiling to classify scrapie strains 
in affected animals (Booth et al., 2004). 
Problems associated with aflatoxin B1 (AFB1) have been known for 
decades and a great deal of research has been conducted on the effects AFB1 at 
the animal level. However, very little research has been done at the gene level. 
Microarrays are being used for global expression profiling to identify candidate 
genes and to map growth, metabolic, and regulatory pathways that control 
important production traits. To date, very few studies have been reported 
regarding the measurement of gene expression in pigs fed AF using microarrays. 
 
OBJECTIVE 
The first objective of the current study was to identify genes whose 
expression are modified in response to aflatoxin B1, and to identify pathways that 
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control growth, development, coagulation, immune function, metabolism, 
detoxification, and antioxidant status of weanling pigs. 
The second objective was to determine if supplementation of turmeric 
powder, containing curcumin, in diets containing aflatoxin B1 would ameliorate 
the adverse effects of aflatoxin B1 on performance of animals and modify hepatic 
gene expression observed in pigs fed aflatoxin B1 diets. 
 
 HYPOTHESIS 
Based on studies at the level of the animal, we hypothesized that aflatoxin 
B1 will cause changes in hepatic expression of genes involved in pigs fed AFB1. 
A second hypothesis would be that the supplementation of curcumin (100 
mg/kg diet containing 1 mg of aflatoxin B1/kg of diet) will prevent or reduce the 
effects of aflatoxins B1. 
 
MATERIALS AND METHODS 
Animal and Diets Procedures 
All animal procedures used were approved by the University of Missouri 
Institutional Animal Care and Use Committee. On d 14 post weaning, 20 
crossbred (PIC genetics) weanling pigs were weighed (average initial weight: 
6.37 kg), ear-tagged, and placed in individual pens with ad libitum access to feed 
and water. Pigs were housed in an environmentally controlled building with 
elevated 1.2 m2 pens with plastic covered grate flooring over a flush system.  
Each pen had a stainless steel nipple waterer and a three-hole nursery feeder. 
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Pigs were assigned to a 2 x 2 factorial arrangement of treatments with two 
concentrations of AFB1 (0 and 1 mg/kg) and two concentrations of curcuminoids 
(CMN, 0 and 100 mg/kg) with five weanling pigs assigned to each of the four 
dietary treatments for 21 days. Diets (Table 3.1) were formulated to meet or 
exceed nutritional requirements of a Phase 2 nursery diet for weanling pigs as 
stated by the National Research Council (NRC, 1998). Dietary treatments 
included: 1) basal diet (BD) containing no AFB1 or CMN;  2) BD + 1.0 mg 
AFB1/kg of diet;  3) BD + 100 mg CMN/kg of diet, and; 4) BD + 100 mg CMN/kg 
of diet + 1.0 mg AFB1/kg of diet. Curcuminoids were supplied by turmeric powder 
containing 3.29% CMN. Aflatoxin B1 (AFB1) was supplied by Aspergillus 
parasiticus (NRRL 2999) culture material containing 750 mg AFB1/kg of culture 
material.  Response variables included growth performance, relative liver and 
kidney weight, blood serum chemistry, and hepatic gene expression. 
On day 21, pigs were euthanized and necropsies performed at the University 
of Missouri Veterinary Diagnostic Laboratory (Columbia, MO). Liver samples 
were collected, placed in 15 mL centrifuge tubes, immediately frozen in liquid 
nitrogen and placed into -80º C freezer. 
 
RNA Isolation and Purification 
 Ribonucleic acid (RNA) was isolated and purified using an Qiagen 
RNeasy® Mini Kit (Qiagen, Valencia,CA). RNA was extracted from liver tissue 
samples (25 mg) and stored in a -80º C freezer. Liver samples were placed 
directly into a suitably sized vessel containing 600 μL of Buffer RLT (supplied by 
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the kit) for disruption and homogenization of lysate using a rotor-stator 
homogenizer for 20 to 40 seconds or until the solution was uniformly 
homogeneous. 
Tubes containing the homogenized solution were centrifuged for three 
minutes at 14,000 rpm. The supernatant formed was removed by pipetting and 
placed into a new microcentrifuge tube. One volume (600 μL) of 70% ethanol 
was added to the clear supernatant and mixed by pipetting. Seven hundred μL of 
the mixed sample was transferred into an RNeasy spin column placed in a 2 mL 
collection tube, and centrifuged for 15 seconds at equal or greater than (>) 
10,000 rpm. The flow-through was discarded, and 700 μL of Buffer RW1 
(supplied by the kit) was added to the RNeasy column. The column was 
centrifuged for 15 seconds at >10,000 rpm to wash the spin column membrane. 
The flow-through was discarded and 500 μL of Buffer RPE (supplied by the kit) 
was added to the RNeasy column. The column was centrifuged for 15 seconds at 
>10,000 rpm to wash the spin column membrane. The flow-through was 
discarded and another 500 μL of Buffer RPE (supplied by the kit) was added to 
the RNeasy column. The column was centrifuged for 2 minutes at >10,000 rpm to 
wash the spin column membrane. The RNeasy spin column was placed in a new 
1.5 mL collection tube (supplied by the kit), then 50 μL of Rneasy-free water 
(supplied by the kit) was added directly to the spin column membrane. Tubes 
were centrifuged for 1 minute at >10,000 rpm to elute the RNA. 
After the isolation and purification procedure was completed, 1 μL of each 
sample was collected for purity and concentration verification. Samples (25 μL 
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RNA) were sent to the DNA Core at Life Sciences Department at University of 
Missouri – Columbia for microarray analysis. 
 
Microarray Analysis 
RNA Amplification, Target Biotin-labeling and Hybridization to Genome 
Array Genechips.  
Complementary RNA preparation, hybridization, and scanning were 
performed following standard protocols recommended by Affymetrix (Santa 
Clara, CA). Half a microgram (μg) of total RNA was used to make the biotin-
labeled antisense RNA (aRNA) target using the MessageAmpTM Premier RNA 
amplification kit (Ambion, Austin, TX) by following the manufacturer’s 
instructions.  Briefly, the total RNA was reverse transcribed to first strand cDNA 
with a oligo(dT) primer bearing a 5’-T7 promoter using ArrayScript reverse 
transcriptase.  The first strand cDNA then underwent second-strand synthesis to 
convert into a double stranded cDNA template for in vitro transcription.  The 
biotin-labeled aRNA was synthesized using T7 RNA transcriptase with biotin-
NTP mix.  After purification, the aRNA was fragmented in 1X fragmentation buffer 
at 94º C for 35 min.   Hybridization solution containing 50 ng/uL of fragmented 
aRNA was hybridized to the genome array genechip (Affymetrix, Santa Clara, 
CA) at 45ºC for 20 hrs.  After hybridization, the chips were washed and stained 
with R-phycoerythrin-streptavidin on Affymetrix fluidics station 450 using fluidics 
protocol Midi_euk2v3-450.  Image data were acquired by Affymetrix Genechip 
scanner 3000 and Affymetrix GCOS software. Microarray data were analyzed 
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using 1-way ANOVA model, the gene list was built using DAVID Bioinformatics 
Resources 6.7®, and validated by quantitative real-time PCR of selected genes. 
Genes with false discovery rates less than 5% and fold change greater than 2.0 
were considerate differentially expressed. 
 
Real-time Quantitative PCR Validation 
For validation of microarray data, six of the most highly expressed genes 
were chosen by function of interest and analyzed by real-time quantitative (RT-q) 
PCR analysis. The same total RNA used for microarray analysis was also 
employed for RT-q PCR. Each sample of total RNA was reverse-transcribed into 
cDNA using the SuperScrip® III First-Strand kit (Invitrogen, Grand Island, NY) 
according to the manufacturer’s instructions. The RT-q PCR was performed in 
triplicate using Power SYBR Green PCR Master Mix (Applied Biosystems). 
Forward and reverse primers (Table 3.2) were designed using the GenBank in 
National Center for Biotechnology Information (NCBI) and synthesized by 
Integrated DNA Technologies (Coralvile, IA). Six genes were selected for 
validation of microarray analysis using RT-qPCR including TNF receptor 
superfamily, member 6 (FAS), Glutathione S-transferase theta 1 (GSTT1), Cyclin 
G1 (CCGN1), Cytochrome P450_2A19 (CYP2A19), Proteasome activator 
subunit (PSME1), and Proteasome activator subunit 3 (PSME3). Homo sapiens 
ribosomal protein L7 (RPL7) was used as a reference gene to account for any 
non-biological variation that occurred in the process. 
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The relative quantification was calculated as a ratio of the target gene to 
the control gene using the ∆∆Ct method. Conditions for RT-q PCR were as 
follows: 50ºC for 2 minutes, 95oC for 10 minutes, 40 cycles of 95oC for 15 
seconds, 63oC for 8 seconds, 72oC for 1 minute, followed by a hold at 4oC. The 
RT-q PCR results were analyzed using the GLM procedure of SAS version 9.2 
statistical package (SAS Inst. Inc., Cary, NC, 2009). Values are presented as 
means + SEM, and differences between treatments means were considered 
significant at P < 0.05. 
 
Statistical Analysis 
Data were analyzed as a 2 x 2 factorial using the GLM procedure of SAS 
(SAS, 2009). Pig was the experimental unit. The means for treatments showing 
significant differences in the analysis of variance were compared using the 
Fisher’s least significant difference procedure (SAS, 2009). 
 
 RESULTS 
 
Performance 
Effects of dietary treatments on growth performance of pigs are summarized 
in Table 3.3. 
Compared to controls, pigs fed the AFB1 diet had statistically (P < 0.05) 
reduced body weight gain (BWG), feed intake (FI), and poor feed efficiency 
(G:F). BWG and FI were not affected by CMN and no CMN*AFB1 interaction was 
observed for BWG and FI. There was, however, a CMN*AFB1 interaction effect 
observed for G:F. Compared to controls, addition of CMN to the basal diet 
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containing no AFB1 resulted in a decrease of G:F in pigs (0.656 vs. 0.733). 
Whereas, the addition of CMN to the diet containing 1.0 mg AFB1/kg, resulted in 
a increase in G:F (0.647 vs. 0.543).  
Effects of dietary treatments on relative organ weights (RW) of pigs are 
summarized in Table 3.3. There was no significant effect of dietary treatments (P 
> 0.05) on relative kidney weight. Pigs fed diets containing 1.0 mg of AFB1/kg 
diet supplemented with CMN had an increased relative liver weight (P < 0.05) 
when compared to control and the other two groups fed either AFB1 or CMN 
alone. There was no (P > 0.05) CMN*AFB1 interaction for relative weights of 
kidney or liver. 
 
Hepatic gene expression - Microarray analysis 
Microarray analysis was conducted with RNA extracted from liver samples 
from four pigs of each treatment: 1) Control (1), 2) AFB1, 3) CMN, and 4) AFB1 + 
CMN. 
A total of 7,639 transcripts were probed. Comparing treatment 1 to 2 (AFB1), 
microarray analysis identified 269 genes (false discovery rate, FDR < 5% and 
fold change, FdC > 2.0) as differentially expressed and highly correlated with the 
treatment, of which, 131 genes were down-regulated and 138 were up-regulated 
in pigs fed AFB1 compared to control. Out of 269 genes, 212 genes were 
recognized by DAVID® Bioinformatics, and subsequently clustered into 33 
distinct functional groups (pathways) (Table 3.4). The differentially expressed 
genes between the treatment groups represented various important pathways 
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such as proteasome, apoptosis, retinol metabolism, lipid metabolism, immune 
response, metabolism of xenobiotics by cytochrome P450, p53 signaling 
pathway, and antigen processing and presentation. Based on the fold 
enrichment, six genes related to apoptosis and detoxification mechanisms were 
chosen to be validated with RT-qPCR, including glutathione S-transferase theta 1 
(GSTT1), proteasome activator subunit 1 (PSME1), proteasome activator subunit 
3 (PSME3), TNF receptor superfamily, member 6 (FAS), Cyclin G1 (CCNG1), 
and cytochrome P450 2A19 (CYP_2A19).  
Microarray analysis showed that there was an increase (P < 0.05) in 
expression of genes FAS (6.60 fold), CCGN1 (6.60 fold), PSME1 (4.03 fold), 
PSME3 (4.03 fold), and CYP2A19 (9.98 fold) in pigs fed 1.0 mg AFB1/kg diet 
compared to the controls. On the other hand, there was a decrease (P < 0.05) in 
expression of gene GSTT1 (8.34 fold) in pigs fed the AFB1 diet in comparison to 
the controls (Figure 3.1). 
Comparing controls to pigs fed 100 mg CMN/kg, there was no difference in 
expression of genes, based on the variables established (FDR < 5% and FdC > 
2.0) in microarray analysis. 
 Comparing controls to pigs fed AFB1 + CMN, microarray analysis 
identified 370 genes (FDR < 5% and FdC > 2.0) as differentially expressed and 
highly correlated with the treatment, of which, 219 genes were down-regulated 
and 151 were up-regulated in pigs fed AFB1 + CMN compared to control. Genes 
were recognized by DAVID® Bioinformatics, and subsequently clustered into 64 
distinct functional groups (Table 3.5). Four of the six genes chosen to be 
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validated had similar expression to pigs fed AFB1 alone. The exceptions were 
GSTT1 that was up-regulated (1.40 fold) and CYP_2A19 that was down-
regulated (6.34 fold) (Figure 3.2). 
 Eighteen common functional groups were found between the two 
treatment groups containing AFB1 and AFB1 + CMN, and are presented in Table 
3.6. Comparing these treatment groups to control, the expression of the genes 
(up or down) in the functional groups were consistent across the two treatments, 
except for threonine biosynthesis (AFB1: down regulated; AFB1 + CMN: up 
regulated) and monosaccharide biosynthesis process (AFB1: up regulated; AFB1 
+ CMN: down regulated). For proteasome metabolism, pigs fed AFB1 alone 
showed up regulation of 26 genes while pigs fed AFB1 + CMN presented up 
regulation of only five genes.  
 
Hepatic gene expression – RT-q PCR analysis 
  Quantitative real-time PCR (RT-qPCR) was used to confirm the validity of 
the microarray results. Five of the six selected differentially expressed genes 
(GSTT1, CYP2A19, FAS, PSME1, and PSME3) had a similar expression pattern 
as observed in microarray results (Figure 3.1) of pig fed AFB1 alone compared to 
control. Cyclin G1 (CCNG1) was not validated by RT-qPCR. In the microarray 
analysis, this gene was up-regulated, whereas in RT-qPCR analysis this gene 
was down-regulated (Figure 3.1). 
 Since there was no difference in hepatic genes expressed in pigs fed BD 
plus CMN compared to control, validation of genes was not conducted. However, 
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RT-qPCR analysis was conducted to verify the expression of the same genes 
validated with the other treatments, AFB1 and AFB1 + CMN. Results in RT-qPCR 
demonstrated that all genes measured had no or little change in expression 
compared to control, indicating that expression of genes in pigs fed CMN was 
similar to pigs fed the control diet. 
 Validation of microarray results with RT-qPCR was also conducted in liver 
samples of pigs fed AFB1 + CMN, compared to control (Figure 3.2). All six genes 
were validated by RT-qPCR, including GSTT1 and CYP_2A19 which were 
differentially expressed when comparing pigs fed AFB1, and AFB1 + CMN to 
control pigs. 
  
DISCUSSION 
 Aflatoxin B1 can be found as a contaminant in several feed ingredients, 
including corn. AFB1 is a concern for the swine industry since corn is one of the 
main ingredients in swine feed and AFB1 contaminated feed causes decreased 
performance and poor health of pigs. In the current study, compared to controls, 
the addition of 1 ppm AFB1 in feed of pigs significantly reduced BWG and G:F. 
Rustemeyer et al. (2011) fed two concentrations of AFB1 (250 and 500 ppb) to 
young growing barrows and also observed a reduction in average daily gain 
(ADG) and average feed intake (AFI).  
Turmeric is a spice made from the rhizome of a tropical Asian plant. This 
deep orange-yellow powder is a common spice in curries and other Asian and 
Middle Eastern cuisines. Turmeric has also been found to be as effective as 
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cortisone in treating acute inflammation, without its toxic side-effects. Turmeric 
can fight cancer by inhibiting tumor growth and stimulating apoptosis (Luper, 
1999). Turmeric has also been shown to inhibit angiogenesis, the process by 
which tumors form new blood vessels and make the transition to becoming 
malignant (Sagar et al., 2006). In the present study, pigs fed diets containing 
CMN had similar BWG and AFI as controls. Similar results were reported by 
Dung et al. (2012) who fed 0.05 or 0.10% turmeric to growing-finishing pigs and 
found no differences in growth rate, feed intake, and feed conversion when 
compared to controls. No improvement in BWG or FI, but an improvement in G:F, 
was observed in the present study, when pigs were fed the diet contaminated 
with 1.0 mg AFB1/kg supplemented with 100 mg CMN/kg compared to pigs fed 
diet containing 1.0 mg AFB1/kg alone. These results demonstrate that the 
presence of CMN in the diet gave partial protection against the adverse effects of 
AFB1, suggesting that higher levels of CMN may be required for maximum 
efficacy. Similar results were demonstrated in broilers by Yarru et al. (2009a) 
where the addition of turmeric powder (TMP), that supplied 74 mg/kg curcumin, 
to the AFB1 diet (1 mg of AFB1/kg of diet) ameliorated the negative effects of 
AFB1 on growth performance. Pigs fed diets supplemented with CMN presented 
similar results to control, except for G:F which was reduced, but the presence of 
CMN in the AFB1 diet was able to improve G:F compared to pigs fed AFB1 alone. 
Similar to the present study, Chamroon et al. (2012) fed different levels (0.05, 
0.10, and 0.20 %) of turmeric to female nursing pigs. The results showed that 
feed conversion ratio and average daily gain was not significantly different 
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among groups. But overall feed intake was greater in pigs fed 0.05 and 0.20% 
turmeric in the diet. Nguyen and Nguyen (2010) also reported that dietary 
supplemented turmeric at 0.05 or 0.10% level in growing-finishing pigs did not 
improve growth rate, feed intake, or feed conversion ratio. 
Quantitative real-time PCR (RT-qPCR) analysis was used to validate the 
expression of genes observed in the microarray analysis. Quantitative real-time 
PCR (RT-qPCR) is a commonly used validation tool for confirming gene 
expression results obtained from microarray analysis, however, microarray and 
qPCR data often result in disagreement (Morey et al., 2006). It is well 
documented that both qPCR and microarray analysis have inherent pitfalls 
(Bustin, 2002; Yang et al., 2002) that may significantly influence the data 
obtained from each method. Additionally, many different platforms exist for both 
microarray and RT-qPCR analyses that have led to debate over which method 
produces the most accurate measurement of gene expression (Barrett and 
Kawasaki, 2003; Zhu et al., 2005). Six genes were chosen for validation of 
expression using RT-qPCR, including FAS, GSTT1, CCGN1, PSME1, PSME3, 
and CYP2A19. Five of the six genes (CCGN1 was not) were validated by RT-
qPCR, comparing the AFB1 treatment alone to control. All six genes were 
confirmed by RT-qPCR from sample of pigs fed AFB1 + CMN. No validation with 
RT-qPCR was possible on samples of pigs fed 100 mg CMN/kg alone because 
there was no change in expression of genes (< 2 fold changes) when compared 
to control. Yarru et al. (2009b) reported that dietary supplementation of 74 mg 
CMN/kg to broilers was able to increase the expression of superoxide dismutase 
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(SOD), glutathione peroxidase (GPx), and epoxide hydrolase (EH), and decrease 
the expression of cytochrome P450 1A1 (CYP1A1) and interleukin 6 (IL-6). 
According to these authors, the increase in expression of these genes, could be 
due the augmented antioxidant status, especially SOD, provided by the 
curcumin. 
The gene CCNG1 (Cyclin G1) was expressed differentially when 
comparing results from microarray to quantitative real-time PCR. This result is 
not a surprise because qRT-PCR is more sensitive and should give more 
accurate results (Shackelford, 2010). According to the same authors, microarray 
analysis is susceptible to several common errors that could influence the final 
results. Most common errors on microarray analysis are: 
Assay Complexity: The cloning and PCR steps required to create and process up 
to one million different sequences, combined with printing these sequences on 
the microarray chip, is extremely complex. Any error in this process will result in 
the misidentification of an expressed sequence, giving false data. 
Signal variation and analysis: The hybridization step, washing, and pixel 
quantification steps are complicated by many factors, including background 
fluorescence, uneven hybridization, fluorophore inactivation by ozone and light 
exposure, temperature variation, cover slip positioning, hybridization time, 
uneven hybridization and dye leaking giving a false signal. 
Incomplete Oligonucleotides and cDNA synthesis: Unrecognized incomplete or 
altered probes will drastically alter the hybridization step, invalidating assay 
results. 
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Data analysis and evaluation: Each microarray data set can consist of several 
million data points giving an enormous amount of raw data to be analyzed. Any 
failure in analysis of the data, for example, not using the appropriate statistical 
tool, could compromise the final data. 
For all the reasons described above, and many other reasons, it is 
important to use RT-qPCR as an additional tool to validate results of microarray 
analysis. 
 The six genes chosen from the microarray analysis to be validated with 
RT-qPCR validation are important to understand the carcinogenic and 
detoxification mechanisms of AFB1. Therefore, a discussion on the function of 
these genes is presented below. 
 
FAS (TNF receptor superfamily, member 6) 
The protein encoded by this gene is a member of the TNF-receptor 
superfamily in member 6. This receptor contains a death domain. It has been 
shown to play a central role in the physiological regulation of programmed cell 
death, and has been implicated in the pathogenesis of various malignancies and 
diseases of the immune system. The autoproteolytic processing of the caspases 
in the complex triggers a downstream caspase cascade, and leads to apoptosis. 
Caspases are a family of cysteine proteases that play essential roles in 
apoptosis, necrosis, and inflammation (Alnemri et al., 1996). The Fas 
receptor  binds the Fas ligand (FasL) and the interaction between Fas and FasL 
results in the formation of the death-inducing signaling complex (DISC), which 
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contains the Fas-Associated protein with Death Domain (FADD), caspase-8 and 
caspase-10. Caspase -8 directly activates other members of the caspase family 
(initiator, including caspase-2, -10, -11 and -12; and downstream effector, 
including caspase-3, -6,  and -7) and triggers the execution of apoptosis of the 
cell (Hornbeck et al., 2012; Cell Signaling, 2012). 
 
GSTT1 (Glutathione S-transferase (GST) theta 1) 
 The GSTT1 is a member of a superfamily of proteins that catalyze the 
conjugation of reduced glutathione to a variety of electrophilic and hydrophobic 
compounds. Glutathione S-transferases are also known for removing pollutants 
and endogenous toxic compounds as part of the phase II detoxification process 
through glutathionylation of diverse electrophilic substrates. It acts as a 
scavenger toward electrophiles of various toxins and protects cells and tissues 
as well as other GST classes (Ito et al., 2011). 
 
 
 
CCGN1 (Cyclin G1) 
Cyclin G1 is one of the target genes of transcription factor p53, and is 
induced in a p53-dependent manner in response to DNA damage. The increase 
in p53 protein levels which occurs in response to genotoxic stress is thought to 
result in transcription of target genes that mediate the varied functions associated 
with the p53 gene.  It therefore seems likely that cyclin G1, being a transcriptional 
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target of p53, may also act as a mediator of p53 functions such as growth 
inhibition, DNA repair and apoptosis (Kimura et al., 2001).  
 
CYP2A19 (Cytochrome P450, family 2, subfamily A, polypeptide 19) 
The cytochrome P450 superfamily (officially abbreviated as CYP) is a 
large and diverse group of enzymes that catalyze the oxidation of organic 
substances. CYPs are the major enzymes involved in drug metabolism and 
bioactivation, accounting for about 75% of the total number of different metabolic 
reactions (Guengerich, 2008).  Cytochrome P450 adds a highly reactive epoxide 
group to aflatoxin, making it highly mutagenic. If not immediately disarmed with 
glutathione, it can attack DNA. The activated aflatoxin binds directly to the DNA 
bases, forming a permanent linkage. Later, when the DNA is repaired or 
duplicated, the cellular machinery may misread the base sequence because of 
the intrusion of the foreign molecule, often causing a change in the base 
sequence or even causing a frame shift. If these mutations happen to fall within 
the regions encoding p53 or an oncogene, they may compromise the regulatory 
function of these molecules, ultimately leading to liver cancer (Goodsell, 2001). 
 
PSME1 and PSME3 (Proteasome activator subunit 1 and 3) 
Proteasome activator subunit 1 and subunit 3 are genes related to 
proteasomal metabolism whose main function is to degrade unneeded or 
damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. 
Both internal and external signals can lead to the induction of apoptosis, or 
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programmed cell death. The resulting deconstruction of cellular components is 
primarily carried out by specialized proteases known as caspases, but the 
proteasome also plays important and diverse roles in the apoptotic process. The 
involvement of the proteasome in this process is indicated by both the increase in 
protein ubiquitination, and of E1, E2, and E3 enzymes that is observed well in 
advance of apoptosis. During apoptosis, proteasomes localized to the nucleus 
have also been observed to translocate to outer membrane blebs which 
is characteristic of apoptosis. 
In the present study, several functional pathways, based on the 
expression of genes, were identified using DAVID® Bioinformatics tools. Of 
which, 33 distinct pathways (Table 3.4) were clusters of genes expressed in pigs 
fed 1.0 mg AFB1/kg feed, and 64 distinct pathways (Table 3.5) in pigs fed 1.0 mg 
AFB1/kg diet supplemented with 100 mg/kg CMN compared to control. Moreover, 
18 pathways were similar between the two treatment groups including up-
regulation of genes in proteasome, nucleus, RNA binding, p53 signaling, antigen 
processing and presentation, and down-regulation of genes in catalytic activity, 
alcohol metabolism, pyruvate, electron carrier activity, retinol metabolism, drug 
metabolism, steroid hormone biosynthesis, metabolism of xenobiotics by cyp 
450, oxygenase, and hexose biosynthetic process. Two out of the 18 pathways 
presented different expression between the two treatments (Threonine: two 
genes down-regulated in treatment AFB1, and two genes up-regulated in 
treatment AFB1 + CMN; and monosaccharide biosynthesis process two genes 
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up-regulated in treatment AFB1 and four genes down-regulated in treatment 
AFB1 + CMN). 
In the current study, we observed increased expression of 14 genes 
related to apoptosis (Table 3.4 and 3.9) when pigs where fed the 1 mg of 
AFB1/kg diet. In agreement with the current study, Rustemeyer et al. (2011) 
observed increased expression of 15 genes related with apoptosis when pigs 
where fed 250 or 500 µg AFB1/kg of diet for a period of 70 days. Apoptosis is a 
complex process that is necessary for regulating cell survival through removal of 
diseased or damaged cells. Because of the liver damage, especially DNA 
damage, caused by AFB1, changes in activity of genes involved in the apoptosis 
process would be anticipated (Rustemeyer et al., 2011).  
Twenty-six genes associated with proteasome metabolism were up-
regulated in liver of pigs fed 1 mg AFB1/kg diet (Table 3.4 and 3.7). Genes such 
as proteasome activator subunit 1, 2, 3, 5, 6 and 10 play a major role in 
degrading unneeded or damaged protein by proteolysis (breaking peptide 
bonds). Also, genes in the proteasome pathway can lead to the induction of 
apoptosis. Up-regulation of these genes in pigs fed 1 mg AFB1/kg diet could 
result in increased apoptosis. Moreover, in pigs fed the AFB1 diet supplemented 
with CMN there was up-regulation of only five genes associated with proteasome 
metabolism. Proteasome inhibition has different effects on apoptosis induction in 
different cell types. In general, the proteasome is not required for apoptosis, 
although inhibiting it is pro-apoptotic in most cell types that have been studied. 
Apoptosis is mediated through disrupting the regulated degradation of pro-growth 
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cell cycle proteins. However, some cell lines are prevented from undergoing 
apoptosis on exposure to proteasome inhibitors. The mechanism for this effect is 
not clear, but is hypothesized to be specific to cells in quiescent states, or to 
result from the differential activity of the pro-apoptotic kinase JNK. The ability of 
proteasome inhibitors to induce apoptosis in rapidly dividing cells has been 
exploited in several recently developed chemotherapy agents such as 
bortezomib and salinosporamide A (Orlowski, 1999). 
 The proteasome degradation pathway is essential for many other cellular 
processes, including response to oxidative stress. Oxidative stress represents an 
imbalance between the production and manifestation of reactive oxygen 
species and a biological system's ability to readily detoxify the reactive 
intermediates or to repair the resulting damage. Disturbances in the 
normal redox state of tissues can cause toxic effects through the production 
of peroxides and free radicals that damage all components of the cell, 
including proteins, lipids, and DNA. However, more severe oxidative stress can 
cause cell death and even moderate oxidation can trigger apoptosis. Since 
aflatoxin has been shown to cause oxidative stress, up regulation of the 
proteasomal pathway is consistent with its biological role.  
 Sixteen genes associated with immune response were down-regulated in 
liver of pigs fed 1 mg AFB1/kg diet (Table 3.4 and 3.8).  Aflatoxin induces 
immunosuppression which can increase the susceptibility of intoxicated animals 
to bacterial, viral, and parasitic infections, by decreasing the concentration of 
immunoglobulins IgM, IgG and IgA (Dhanasekaran et al., 2011). Watzl et al. 
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(1999) hypothesized that the toxicity of AFB1 and its locally generated 
metabolites in the intestinal tissue may result in a disturbed intestinal integrity 
and, subsequently, in an impaired immune response towards dietary proteins. 
The impairment of protein synthesis caused by dietary aflatoxin could account for 
the lack of humoral immunity without the necessity of B and T cell destruction 
(Wyatt, 1991). Corrier (1991) indicated that AFB1 has a selective inhibitory effect 
on cell-mediated immunity and T-lymphocytes blastogenesis in response to T-
cell specific mitogens. Richard (2007) reported that AFB1 decreased the 
percentage of peripheral blood T lymphocyte and contents of interleukin 2 and 6 
(IL-2 and IL-6). Yarru et al. (2009b) observed down-regulation of genes 
associated with immune response of birds fed 1 mg AFB1/kg diet, which is in 
agreement with the present study. Qian et al. (2013), in a study of short and long 
term exposure of rats to AFB1, observed immunosuppressive effects through 
inhibitory effects on gene expression in rats exposed to AFB1 short-term, while 
prolonged exposure up-regulated cytokines and proinflammatory genes to 
enhance inflammation and apoptosis. 
In the present study, up regulation of 26 and 30 genes on intracellular 
metabolism was observed in pigs fed diets 1.0 mg AFB1/kg and in pigs fed 1.0 
mg AFB1/kg supplemented with 100 mg CMN/kg diet, respectively. Harris et al. 
(1998) stated that intracellular transport could increase intracellular levels of 
AFB1 in the cell and eventual transport into the nucleus, increasing the genotoxic 
potential of AFB1. Zhou et al. (2012) observed that some proton dependent 
transport mechanisms modulate cellular accumulation of AFB1. Oxidative 
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damage is one of the underlying mechanisms of the cytotoxicity and 
carcinogenicity of AFB1 (Shen et al. 1996). The presence of AFB1 increases the 
presence of free radical resulting in chromosomal damage, lipid peroxidation and 
DNA oxidation (Lee et al., 2010). 
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CONCLUSION 
 Based on the results of this experiment, we concluded that the 
supplementation of 100 mg CMN/kg diet to pigs fed diets containing 1.0 mg 
AFB1/kg reduced the toxic effects of AFB1, improved performance (except for 
feed efficiency where pigs fed CMN diet had reduced G:F compared to control.) 
when compared to pigs that were fed a diet containing only 1.0 mg AFB1/kg. 
There was no significant effect when pigs where fed a diet supplemented with 
CMN alone compared to the control. 
 Pigs supplemented with 1.0 mg AFB1/kg diet for 21 days had physiological 
responses associated with altered hepatic gene expression in metabolic 
pathways such as apoptosis, proteasome, immune response, and p53 signaling 
pathways.  
The supplementation of CMN in diets containing AFB1 was able to counteract 
the effects of AFB1 by increasing the expression of GSTT1 and decreasing the 
expression of CYP_2A19, alleviating the biotransformation of aflatoxin B1 to its 
carcinogenic form (AFB1-8,9-epoxide - AFBO) and increasing the conjugation 
with AFBO and, consequently, increasing its excretion.  
Quantitative real time –PCR (qRT-PCR) was able to confirm the expression 
of several genes, except for CCNG1 (Cyclin G1) which in microarray analysis 
was up-regulated whereas in qRT-PCR this same gene was down-regulated. 
 In our study, we hypothesized that aflatoxin B1 would cause changes in 
hepatic expression of genes involved in pigs fed AFB1. This hypothesis was 
confirmed since we observed changes in expression of several genes. We also 
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hypothesized that the supplementation of curcumin (100 mg/kg diet containing 1 
mg of aflatoxin B1/kg of diet) would prevent or reduce the effects of aflatoxins B1. 
The addition of CMN in diet containing AFB1 was not able to alleviate the 
negative effects of AFB1 on performance, but was able to change the expression 
of genes associated with apoptosis and proteasome, partially confirming our 
hypothesis. 
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Table 3.1 – Ingredient and nutrient composition of diets (as-fed1) 
Item % of Diet 
Ingredient  
   Corn, Yellow dent 50.17 
   Soybean Meal, 48% CP 27.50 
   Whey, dried 10.00 
   Animal Palsma, spray-dried 2.50 
   Choice white grease 5.00 
   Dicalcium phosphate, 21% P 2.05 
   Limestone 0.87 
   Vitamin Premix2 0.50 
   Salt, NaCl 0.20 
   L-Lysine HCL 0.15 
   Mineral Premix 3 0.15 
   DL-Methionine 0.065 
1Diet formulated to contain: 22% CP, 0.9% Ca, 0.55% available P, 1.25% total 
lysine, and 1.12% SID Lysine. 
2Vitamin Premix supplied per kilogram of diet: retinyl acetate, 11,000 IU; 
cholecalciferol, 1,100 IU; DL-α-tocophereryl acetate, 44.1 IU; menadione Na 
dimethylpyrimidinol bisulfate, 4.0 mg; vitamin B12, 30.3 μg; riboflavin, 8.3 mg; D-
Ca-pantothenate, 28.1 mg; nicotinamide, 33.1 mg; choline chloride, 551.3 mg; D-
biotin, 0.22 mg; and folic acid, 1.65 mg. 
3Mineral Premix supplied per kilogram of diet: Zn, 165 mg (ZnSO4); Fe, 165 mg 
(FeSO4H2O); Cu, 16.5 mg (CuSO4H2O); Mn, 33 mg (MnSO4); I, 0.3 mg Ca (IO3); 
and Se, 0.3 mg (NaSeO3). 
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Table 3.3 – Effects of AFB1 on growth performance of weanling pigs1  
Treatment2 Performance3  Organ RW4 
BWG FI G:F  Liver Kidney 
(kg) (kg) (kg:kg)  (%) 
    Control 8.55a 11.64 a 0.733 a  2.91 b 0.561 
    BD + CMN 8.04 a 12.32 a 0.656 b  3.12 b 0.563 
    BD + 1.0 AFB1 5.12 b 9.45 b 0.543 c  2.98 b 0.517 
    BD + 1.0 AFB1 + CMN 5.79 b 8.94 b 0.647 b  3.53 a 0.683 
    Pooled S.E.M. 0.52 0.73 0.03  0.13 0.07 
P-value       
    CMN 0.8784 0.9093 0.6065  0.0107 0.2343 
    AF <0.0001 0.0016 0.0012  0.0868 0.5855 
    CMN * AFB1 0.2772 0.4300 0.0025  0.2212 0.2435 
1 Data are means of five pigs per treatment. 
2 Control = Basal diet (BD); BD + 1.0 AF = BD + 1.0 ppm AFB1; BD + CMN = BD 
+ 100 ppm CMN; BD + 1.0 AF + CMN = BD + 1.0 ppm AFB1 + 100 ppm CMN. 
3 BWG = Body weight gain; AFI = Average feed intake; G:F = Gain:Feed. 
a-d Means in a row with different superscripts differ significantly (P < 0.05).  
4 Relative organ weights expressed as percent body weight. 
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Table 3.4 – Pathways represented by the genes identified as differentially 
expressed from RNA-microarray results of pigs fed 1 mg of AFB1/ kg diet 
compared to control (Total of 269 genes differentially expressed, of which 138 
were up regulated and 131 down regulated). 
Pathways Number of genes Expression 
Proteasome 26 up 
Intracelular 26 up 
Metabolic process 19 down 
Hydrolase activity 17 up 
Catalytic activity 17 down 
Immune response 16 down 
Apoptosis 14 up 
Nucleus 10 up 
Guanyl Binding 10 up 
Oxidoreductase activity  10 down 
Lipid Metabolism 9 down 
Alcohol Metabolism 8 down 
Pyruvate 7 down 
RNA* binding 6 up 
GTP* binding 5 up 
Nucleoside-triphosphatase activity 5 up 
Pyrophosphatase activity 5 up 
Glysolysis/gluconeogenesis 5 down 
Ion binding 5 down 
Cabohydrate metabolic process 5 down 
Electron carrier activity 5 down 
Induction 4 up 
p53 signaling pathway 4 up 
Antigen processing and presentation 4 up 
Retinol Metabolism 4 down 
Drug Metabolism 4 down 
PPAR* signaling pathway 4 down 
Steroid hormone biosynthesis 3 down 
Metabolism of xenoviotics by cyp 450 3 down 
Oxygenase 3 down 
Threonine 2 down 
Monosaccharide biosynthesis process 2 up 
Hexose Biosynthetic process 2 down 
*GTP = guanosine triphosphate; RNA = ribonucleic acid; PPAR = peroxisome 
proliferator-activated receptor 
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Table 3.5 – Pathways represented by the genes identified as differentially 
expressed from RNA-microarray results of pigs fed 100 mg CMN/kg + 1 mg 
AFB1/ kg diet compared to control (Total of 370 genes differentially expressed, of 
which 151 were up regulated and 219 down regulated). 
Pathways Number of genes Expression 
Catalytic activity 31 down 
Intracellular 30 up 
Cellular process 28 up 
Organelle 21 up 
Cytoplasm 16 down 
Oxidation reduction 13 down 
Transition metal ion binding 12 down 
Nucleic acid binding 12 up 
Acetylation 11 up 
Nucleus 11 up 
Electron carrier activity 8 down 
Drug metabolism 7 down 
Iron 7 down 
Carbohydrate metabolic process 7 down 
Alcohol metabolic process 6 down 
Retinol metabolism 5 down 
Metabolism of xenobiotics by cyp450 5 down 
Flavoprotein 5 down 
FAD 5 down 
Monooxygenase 5 down 
Organic acid metabolic process 5 down 
Oxoacid metabolic process 5 down 
Carboxylic acid metabolic process 5 down 
Cellular ketone metabolic process 5 down 
Endoplasmic reticulum 5 down 
Tetrapyrrole binding 5 down 
Cofactor binding 5 down 
Proteasome 5 up 
p53 signaling pathway 5 up 
Antigen processing and presentation 5 up 
RNA binding 5 up 
Complement and coagulation cascades 4 down 
Heme 4 down 
Monosaccharide metabolic process 4 down 
Hexose metabolic process 4 down 
Coenzyme binding 4 down 
Small GTPase mediated signal transduction 4 up 
Active transmembrane transporter activity 4 up 
 64 
 
Table 3.5 – Continued   
Pathways Number of genes Expression 
Pantothenate and CoA biosynthesis 3 down 
Prion diseases 3 down 
Steroid hormone biosynthesis 3 down 
Pyruvate metabolism 3 down 
Microsome 3 down 
Glucose metabolic process 3 down 
Thyroid cancer 3 up 
Prenylation 3 up 
Caffeine metabolism 2 down 
Nucleobase metabolic process 2 down 
Endoribonuclease activity 2 down 
Pancreatic ribonuclease activity 2 down 
Sulfotransferase activity 2 down 
Threonine protease 2 up 
Carbonyl reductase (NADPH) activity 2 up 
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Table 3.6 – Pathways represented by the genes identified as differentially 
expressed from RNA-microarray results of pigs fed AF and AF+CMN. 
Pathways Control vs AFB1 
 Control vs AFB1 
+CMN 
 
# 
genes Expression 
 # 
genes Expression 
Intracellular 26 up  30 up 
Proteasome 26 up  5 up 
Nucleus 10 up  11 up 
RNA* binding 6 up  5 up 
p53 signaling pathway 4 up  5 up 
Antigen processing and 
presentation 4 up 
 
5 up 
Catalytic activity 17 down  31 down 
Alcohol Metabolism 8 down  6 down 
Pyruvate 7 down  3 down 
Electron carrier activity 5 down  8 down 
Retinol Metabolism 4 down  5 down 
Drug Metabolism 4 down  7 down 
Steroid hormone  3 down  3 down 
Metabolism of xenobiotics 
by cyp 450 3 down 
 
5 down 
Oxygenase 3 down  5 down 
Hexose Biosynthetic  2 down  4 down 
Threonine 2 down  2 Up 
Monosaccharide biosynt.  2 Up  4 down 
* RNA = ribonucleic acid; 
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Figure 3.1 – Microarray validation with RT-qPCR for genes expressed in liver 
samples of pigs fed 1.0 mg of AFB1/kg diet compared to control. Expression of 
genes selected for validation are represented as bars for each analysis (1st bar – 
microarray, 2nd bar – RT-qPCR). Genes selected for validation are the following: 
TNF receptor superfamily, member 6 (FAS), Glutathione S-transferase theta 1 
(GSTT1), Cyclin G1 (CCGN1), Proteasome activator subunit 1 (PSME1), 
Proteasome activator subunit 3 (PSME3), and Cytochrome P450_2A19 
(CYP2A19). Homo sapiens ribosomal protein L7 (RPL7) was used as a reference 
gene to account for any non-biological variation that occurred in the process. 
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Figure 3.2 – Microarray validation with RT-qPCR for genes expressed in liver 
samples of pigs fed 1.0 mg of AFB1/kg diet supplemented with 100 mg CMN/kg 
diet compared to control. Expression of genes selected for validation are 
represented as bars for each analysis (1st bar – microarray, 2nd bar – RT-qPCR). 
Genes selected for validation are the following: TNF receptor superfamily, 
member 6 (FAS), Glutathione S-transferase theta 1 (GSTT1), Cyclin G1 
(CCGN1), Proteasome activator subunit 1 (PSME1), Proteasome activator 
subunit 3 (PSME3), and Cytochrome P450_2A19 (CYP2A19). Homo sapiens 
ribosomal protein L7 (RPL7) was used as a reference gene to account for any 
non-biological variation that occurred in the process. 
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Figure 3.3 – Microarray validation with RT-qPCR for gluthathione S-transferase 
theta 1 - GSTT1 (left) and cytochrome P450_2A19 - CYP_2A19 (right) genes, in 
liver samples of pigs fed 1.0 mg AFB1/kg diet and 1.0 mg AFB1/kg diet 
supplemented with 100 mg CMN/kg diet. 
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CHAPTER IV 
 
EFFECTS OF AFLATOXIN AND TURMERIC (Curcuma longa) POWDER 
CONTAINING CURCUMIN, ON GROWTH PERFORMANCE AND  
HEPATIC GENE EXPRESSION OF TURKEY POULTS  
FED DIETARY TREATMENTS FROM  
HATCH TO DAY 21 
 
 
ABSTRACT 
 
 
The objective of the present study was to determine if turmeric powder 
containing curcuminoids would be able to prevent or reduce the negative effects 
associated with oxidative stress and decreased performance in young turkey 
poults fed AF. Two hundred day-old female poults were purchased from a 
commercial hatchery and assigned to one of eight treatments from hatch to day 
21. Poults were weighed, wing-banded, and assigned to pens in stainless steel 
batteries. A Completely Randomized Designed (CRD) was used with five 
replicate pens of five poults assigned to each of eight dietary treatments from 
hatch to 21 days.  The dietary treatments included: 1) a basal diet (BD) 
containing no aflatoxin (AF) or curcumin (CMN); 2) BD plus 296 mg CMN/kg 
diet); 3) BD plus 200 µg AFB1/kg diet; 4) BD plus 200 µg AFB1/kg diet plus 74 mg 
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CMN/kg diet; 5) BD plus 200 µg  AFB1/kg diet plus 148 mg CMN/kg diet, 6) BD 
plus 200 µg AFB1/kg diet plus 222 mg CMN/kg diet; 7) BD plus 200 µg AFB1/kg 
diet plus 296 mg CMN/kg diet, and; 8) BD plus 20 µg total aflatoxins (AFTotal – 
AFB1, AFB2, AFG1, and AFG2) per kilogram of diet. Curcumin was supplied by 
turmeric powder containing 3.29% total curcuminoids. Aflatoxin reduced (P < 
0.05) average weight gain, average feed intake and feed efficiency. Curcumin, 
regardless of inclusion rate, was not effective in ameliorating the toxic effects of 
200 µg AFB1/kg diet in female poults fed dietary treatments from hatch to day 21.  
Results also indicate that 20 µg/kg of total AF/kg diet (AFB1, AFB2, AFG1, and, 
AFG2), the FDA’s action level for AF in poultry diets, does not affect growth 
performance but does cause biological changes in poults including changes in 
gene expression. At the end of the three week experimental period, liver samples 
from three birds per treatment were collected to evaluate changes in gene 
expression involved in complement and coagulation cascade, pathways in 
cancer, focal adhesion, EMC-receptor interaction, regulation of actin 
cytoskeleton, cell cycle, glutathione metabolism, and metabolism of xenobiotics 
by cytochrome P450. Changes in gene expression were determined using RNA 
sequencing techniques. The highest number of differentially expressed genes 
were found when birds were fed 200 µg AFB1/ kg diet alone compared to control. 
Moreover, the addition of 74 mg CMN/kg diet was able to alleviate the effects of 
AFB1 on expression of genes related to the pathways described. The FDA’s 
action level for AF in turkey diets caused the lowest numbers of differentially 
expressed genes, suggesting that even at low levels, aflatoxin may cause 
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alteration in the expression of specific genes. Higher levels of curcumin should 
be tested to determine its efficacy against the negative effects of AFB1 fed to 
turkey poults. 
 
INTRODUCTION 
 
 Aflatoxins (AF) are secondary metabolites produced by Aspergillus 
parasiticus and Aspergillus flavus that have been found to be major contaminants 
of common poultry ingredients (Smith et al., 1995). Aflatoxin B1 (AFB1) is the 
most biologically active form of AF, causing poor performance, liver lesions and 
immunosuppression (Ledoux et al., 1998). Since the early 1990s, evidence has 
accumulated that oxidative damage is associated with AFB1 toxicity (Towner et 
al., 2002). Specifically, an increase in production of reactive oxygen species 
(ROS) was observed during aflatoxicosis using direct and indirect methods of 
measurement (Kodama et al., 1990; Shen et al., 1996; Rastogi et al., 2001). 
Shen et al. (1996) and Towner et al. (2002) proposed that cytochrome P-450 
metabolism of AFB1 is a significant source of ROS production during AFB1 
exposure. Subsequently, Yarru et al. (2009a) showed that genes involved with 
phase I metabolism, specifically genes that code for cytochrome P-450 (CYP450) 
enzymes are up regulated in broilers exposed to AFB1. Increased production of 
CYP450 enzymes correlates to greater generation of ROS thus placing the 
broiler in an elevated state of oxidative stress leading to increased cell damage 
and even cell death (Kumar et al., 2006). 
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 Adsorbents have been employed to ameliorate the toxic effects of AFB1 in 
poultry diets, and certain aluminosilicate binders have shown beneficial effects 
(Phillips et al., 1990; Ledoux et al., 1998). Because lipid peroxidation plays a 
major role in the toxicity of AF, a protective effect of antioxidants is possible 
(Galvano et al., 2001). Plant compounds like coumarins, flavonoids, and 
curcuminoids have been showed to inhibit the biotransformation of AF to their 
epoxide derivatives (Lee et al., 2001). Turmeric (Curcuma longa), a medicinal 
plant native to the Asian subcontinent, is known to possess antimicrobial and 
antioxidant properties. The powder of dried roots and rhizomes of turmeric is 
used as one of the spices in Indian curries and other cuisine. The curcuminoids, 
yellowish pigments present in turmeric powder, have shown protective effects 
against AFB1 (Soni et al., 1997). The most recent dietary approach to prevent 
mycotoxicoses in poultry is the combined use of antioxidants and adsorbents 
(Gowda, 2008).  
 Due to the increased production of ROS during AF exposure, dietary 
supplementation with antioxidants has been shown to reduce the negative effects 
of AF on animal performance and cellular damage due to oxidative stress. Yarru 
et al. (2009b) showed that the inclusion of 0.5% turmeric (Curcuma longa) 
powder (CMN), that provided 74 mg/kg of total curcuminoids, to a diet containing 
1.0 mg AFB1/kg increased body weight gain above that of broilers fed a diet that 
contained only AFB1, and caused a decrease in expression of genes that code 
for CYP450 enzymes. 
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OBJECTIVE 
 
The objective of the current study was to determine if turmeric powder, 
containing curcuminoids, would be able to prevent or reduce the negative effects 
associated with oxidative stress and decreased performance in young turkey 
poults fed AF. 
 
HYPOTHESIS 
 
Based on studies at the level of the animal, we hypothesized that 200 µg 
aflatoxin B1 per kilogram in the diet will cause changes in the expression of 
genes in turkey poults. 
A second hypothesis would be that supplementation of curcumin (CMN) 
up to 296 milligrams per kilograms will ameliorate the toxic effects of aflatoxin B1 
in turkey poults.  
The third hypothesis is that the supplementation of aflatoxin B1 at the 
Food and Drug Administration (FDA) regulatory level will not have negative 
effects on growth performance or cause changes in hepatic gene expression in 
turkey poults. 
 
MATERIALS AND METHODS 
Animals and Diets Procedures 
All animal procedures used were approved by the University of Missouri 
Institutional Animal Care and Use Committee. 
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Two hundred day-old female poults were purchased from a commercial 
hatchery and assigned to one of eight treatments from hatch to day 21. Poults 
were weighed, wing-banded, and assigned to pens in stainless steel batteries.  
Poults were maintained on a 24 hour constant-light schedule in an 
environmentally controlled room and allowed ad libitum access to feed and 
water.  
A Completely Randomized Designed (CRD) was used with five replicate 
pens of five poults assigned to each of eight dietary treatments from hatch to 21 
days.  Diets were formulated to meet or exceed nutritional requirements for 
poults (Table 4.1) during the first 21 days as stated by the National Research 
Council (NRC, 1994). Dietary treatments included: 1) a basal diet (BD) containing 
no aflatoxin (AF) or curcumin (CMN); 2) BD plus 296 mg CMN/kg diet); 3) BD 
plus 200 µg AFB1/kg diet; 4) BD plus 200 µg AFB1/kg diet plus 74 mg CMN/kg 
diet; 5) BD plus 200 µg  AFB1/kg diet plus 148 mg CMN/kg diet, 6) BD plus 200 
µg AFB1/kg diet plus 222 mg CMN/kg diet; 7) BD plus 200 µg/kg diet AFB1 plus 
296 mg CMN/kg diet, and; 8) BD plus 20 µg total aflatoxins (AFTotal – AFB1, AFB2, 
AFG1, and AFG2) per kilogram of diet. Curcumin was supplied by turmeric 
powder containing 3.29% total curcuminoids. Diets were analyzed at Veterinary 
Medical Diagnostic Lab, in the Toxicology Department at University of Missouri – 
Columbia, to confirm the concentration of aflatoxin in the diets. Level of aflatoxins 
in the diet containing FDA regulatory level of aflatoxin for immature animals were: 
AFB1: 16.45 µg/kg; AFB2: 1.15 µg/kg; AFG1: 3.4 µg/kg; and AFG2: 1.15 µg/kg 
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(AFTotal = 22.15 µg/kg). Treatment diets contaminated with AFB1 were also 
analyzed to confirm the concentration of 200 mg AFB1/kg diet. 
On day 20, poults and feed were weighed to measure body weight gain 
(BWG) and feed intake (FI), and to calculate feed conversion (FC).  
At the end of the 21 d study, poults were euthanized using Carbon Dioxide 
(CO2) and blood was collected via cardiac puncture for determination of serum 
chemistries. Blood samples were centrifuged (Sorvall, RC 3 B plus) at 1,400 x g 
for 30 minutes at 7ºC and serum was separated and frozen until analysis. Serum 
analyses for all components of biochemical and enzyme profiles were performed 
by the Veterinary Medicine Diagnostic Lab using an auto-analyzer (Kodak 
Ektachem, Rochester, NY).  
 Liver and kidneys were collected from three birds from each replicate, 
totaling 15 samples for each treatment group, and weighed for determination of 
relative weights of kidney and liver. In addition, liver samples were collected from 
four treatments (Control, 200 µg AFB1/kg diet, 200 µg AFB1/kg diet 
supplemented with 74 mg CMN/kg diet, and 20 µg AFTotal/kg diet) placed on pre-
cut aluminum foil, sliced, immediately frozen in liquid nitrogen and placed into -
80ºC freezer for subsequent sequencing analysis. 
 
Statistical Analysis on performance 
Data were analyzed as a one way ANOVA using the GLM procedures of 
SAS (SAS, 2009). Battery pen was used as the experimental unit.  The means 
for treatments showing significant differences in the analysis of variance were 
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compared using Fisher’s protected least significant difference (LSD) test. 
Significance was accepted at P < 0.05. 
RNA Isolation and Purification 
 Ribonucleic acid (RNA) isolation and purification was achieved using the 
Qiagen RNeasy® Mini Kit (Qiagen, Valencia,CA). Liver samples were removed 
from the -80ºC freezer and 25 mg of each sample was used for RNA purification. 
Liver samples were placed directly into a suitably sized vessel containing 600 μL 
of Buffer RLT (supplied by the kit) for disruption and homogenization of lysate 
using a rotor-stator homogenizer for 20 to 40 seconds or until the solution was 
uniformly homogeneous. 
Tubes containing the homogenized solution were centrifuged for 3 minutes at 
full speed (14,000 rpm). The supernatant formed was removed by pipetting and 
placed into a new micro-centrifuge tube. One volume (600 μL) of 70% ethanol 
was added to the cleared lysate and mixed by pipetting. Seven hundred μL of the 
mixed sample was transferred into an RNeasy spin column placed in a 2 mL 
collection tube, and then centrifuged for 15 seconds at 10,000 rpm. The flow-
through was discarded and 700 μL of Buffer RW1 (supplied by the kit) was added 
to the RNeasy column. The column was centrifuged for 15 seconds at 10,000 
rpm to wash the spin column membrane. The flow-through was discarded and, 
500 μL of Buffer RPE (supplied by the kit) was added to the RNeasy column. The 
column was centrifuged for 15 seconds at 10,000 rpm to wash the spin column 
membrane. The flow-through was discarded and additional 500 μL of Buffer RPE 
(supplied by the kit) was added to the RNeasy column. The column was 
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centrifuged for 2 minutes at 10,000 rpm to wash the spin column membrane. The 
RNeasy spin column was placed in a new 1.5 mL collection tube (supplied by the 
kit) and 50 μL of Rneasy-free water (supplied by the kit) was added directly to the 
spin column membrane. Tubes were centrifuged for 1 minute at 10,000 rpm to 
elute the RNA. 
After the isolation and purification procedure was completed, 1 μL of each 
sample was collected for purity and concentration verification. Samples 
(concentration of 25 μg of RNA) were sent to the DNA Core at the Life Sciences 
Department at University of Missouri – Columbia for RNA sequencing analysis. 
 
Illumina TruSeq RNA Library Preparation and Sequencing 
The RNA-Seq was conducted at the University of Missouri DNA Core 
(Columbia, MO). Libraries were constructed following the manufacturer’s protocol 
with reagents supplied in Illumina’s TruSeq RNA sample preparation kit (#RS-
930-2001).  Extracted and purified RNA of liver samples from three animals per 
treatment were used, including: 1) BD containing no AF or CMN; 3) BD plus 200 
µg AFB1/kg diet; 4) BD plus 200 µg AFB1/kg diet plus 74 mg CMN/kg diet; and 8) 
BD plus 20 µg total aflatoxins/kg diet (AFTotal). 
Briefly, the poly-A containing mRNA was purified from total RNA, RNA 
was fragmented, double-stranded cDNA was generated from fragmented RNA, 
and the index containing adapters were ligated to the ends.  Total RNA (2 µg) 
was first incubated in a thermal cycler for 5 minutes at 65oC in a total volume of 
50 µL in a 96-well PCR plate.  The plates were removed and incubated an 
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additional 5 minutes at room temperature allowing RNA to bind to the poly-T 
oligo-attached magnetic beads.  Beads were washed by placing the PCR plate 
on the magnetic stand at room temperature for 5 minutes and the supernatant 
was discarded.  Bead Washing Buffer (200 µL) was added and returned to the 
magnetic stand for 5 minutes.  Supernatant was removed and discarded.  The 
plates were removed from the magnetic stand and Elution Buffer (50 µL) was 
added to each well.  The plate was incubated at 80oC for 2 minutes and then 
placed at room temperature.  RNA was rebound to beads with the addition of 
Bead Binding Buffer (50 µL) and incubated for 5 minutes at room temperature.  
Beads were again washed as previously described.   
First strand complementary DNA (cDNA) synthesis was performed by 
adding the Elute, Prime, and Fragment Mix (19.5 uL) to each well.  The mixture 
was incubated for 8 minutes at 94oC.  The plates were placed on the magnetic 
stand at room temperature for 5 minutes.  From each plate, 17 µL of the 
fragmented and primed RNA was transferred to a new PCR plate.  First Strand 
Master Mix and Superscript II mix (8 µL) were added to each well and gently 
mixed.  Incubation was performed in a thermal cycler with the program:  
25oC(10:00)+42oC(50:00)+70oC(15:00).   
Second strand cDNA synthesis was performed by the addition of Second 
Strand Master Mix (25 uL) to each well.  The mixture was incubated at 16oC for 1 
hour.  Aline PCRClean beads (90 µl) were added to each well containing 50 µL 
of ds cDNA.  The plates were incubated at room temperature for 15 minutes and 
placed on the magnetic stand for 5 minutes.  The supernatant (135 µL) was 
 86 
 
removed and discarded.  Each well was washed by addition of 200 µL of 80% 
EtOH, incubated at room temperature for 30 seconds, and the supernatant 
removed.  Wash steps were repeated once and plates were allowed to dry on a 
magnetic stand for 15 minutes.  Re-suspension Buffer (52.5 µL) was then added 
to each well.  The plates were returned to the magnetic stand at room 
temperature for 5 minutes and 50 µL of supernatant was transferred to a new 
PCR plate.  Fragment overhang ends were converted to blunt ends by the 
addition of the End Repair Mix (40 µL) to each well and incubated at 30oC for 30 
minutes.  Aline PCRClean beads (160 µL) were added to each well which 
contained 100 µL of End Repair Mix.  The plate was incubated at room 
temperature for 15 minutes.  Supernatant (127.5 µL) was removed and 
discarded.  Each well was washed with 80% EtOH as described previously.  The 
dried pellet was re-suspended in Re-suspension Buffer (20 µL) and 15 µL was 
transferred to a new PCR plate.  The 3’ ends of the fragments were adenylated 
with the addition of A-Tailing Mix (12.5 µL) to each well and then incubated for 30 
minutes at 37oC. The DNA Ligase Mix (2.5 µL) and a single RNA Adapter Mix 
(2.5 µL) were added to each well which was then incubated for 10 minutes at 
37oC.  The ligation reaction was stopped with the addition of Stop Ligase Mix (5 
µL).  Aline PCRClean beads (42 µL) were added to each well.  The plates were 
incubated at room temperature for 15 minutes.  The supernatant (79.5 µL) was 
removed and discarded.  Each well was washed with 80% EtOH as previously 
described. The dried pellet was resuspended in Resuspension Buffer (52.5 µL) 
and 50 µL was transferred to a new PCR plate.  Aline PCRClean beads (50 µL) 
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were added to each well.  The plates were incubated at room temperature for 15 
minutes.  The supernatant (95 µL) was removed and discarded.  Each well was 
again washed with 80% EtOH as previously described.  The dried pellet was 
resuspended in Resuspension Buffer (22.5 µL) and 20 µL was transferred to a 
new PCR plate. DNA fragments were enriched by adding PCR Primer Cocktail (5 
µL) and PCR Master Mix (25 µL) to each well.  PCR amplification was performed 
as follows:  
 98oC(0:30)+[98oC(0:10)+60oC(0:30)+72oC(0:30)] x 15 cycles +72oC(5:00).   
The amplified cDNA constructs were purified by addition of Aline PCRClean 
beads (50 µL) to each well.  The plates were incubated at room temperature for 
15 minutes.  The supernatant (95 µL) was removed and discarded.  Each well 
was again washed with 80% EtOH as previously described.  The dried pellet was 
resuspended in Resuspension Buffer (32.5 µL), incubated at room temperature 
for 2 minutes, and then placed on the magnetic stand for 5 minutes.  The 
supernatant (30 µL) was transferred to low binding microcentrifuge tube for 
storage.  The final construct of each purified library was evaluated using the 
BioAnalyzer 2100 automated electrophoresis system, quantified with the Qubit 
flourometer using the quant-iT HS dsDNA reagent kit (Invitrogen), and diluted 
according to Illumina’s standard sequencing protocol for sequencing on the 
HiSeq 2000. 
 Data generated were analyzed by NextGENe® software 
(SOFTGENETICS®, State College, PA) through the Remote Desktop at 
“mugenomics1.col.missouri.edu”.  Data were downloaded and decompressed 
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through the NextGENe® software, following the protocol instructions. After the 
decompressing procedure was completed, the data generated were converted to 
adequate format (Illumina fastq) and trimmed according to the protocol 
instructions. When the trimming was concluded, data were ready for the tilling 
and the turkey DNA library was generated. At this point, the data were aligned 
and compared to the DNA library, generating a spreadsheet, and data containing 
all the genes expressed were analyzed according to the expression of the 
specific genes (down- or up-regulated). Data generated were trimmed, de novo 
aligned, assembled, and the transcripts were measured using NextGENe® 2.17 
beta. Differential gene list was built using edgeR Bioconductor ® package, and 
enrichment analysis of functional clusters and pathways was performed using 
DAVID Bioinformatics Resources 6.7®. 
 
Statistical analysis on gene expression 
Statistical analysis was conducted using edgeR Bioconductor® software 
and the voom() function of limma Bioconductor® package to verify expression of 
selected genes of treatments compared to control. Genes with P < 0.05 
difference in expression compared to control were considered differentially 
expressed. The normalization procedure used to calculate the expression of 
genes was Reads per Kilobase per Million reads (RPKM). The natural 
representation of gene read counts was the Poisson distribution of the form f(n, ג) 
= (גn e-ג)/n! where n is the number of read counts and ג is a real number equal to 
the expected number of reads from transcripts fragments. Generally the variance 
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of gene expression across multiple biological replicates is larger than its mean 
expression values, causing an overexpression. To correct this overexpression, 
edgeR used the related negative binominal distribution (NB) where the 
relationship between the variance v and mean µ is defined as v = µ + αµ2 where 
α is the dispersion factor (Rapaport et al., 2013). Once the data were processed 
and the dispersion estimates were moderate, the TopTags function was used to 
tabulate the top differentially expressed genes. 
 
 
RESULTS  
 
Performance 
Effects of dietary treatments on growth performance of turkeys are 
summarized in Table 4.2. Compared to control, inclusion of 296 mg CMN/kg diet 
alone in the basal diet did not affect (P > 0.05) average weight gain (AWG), and 
average feed intake (AFI). However, the addition of 200 µg AFB1/kg diet to the 
basal diet significantly reduced (P < 0.05) AWG and AFI compared to control. 
The inclusion of incremental levels of CMN (from 74 to 296 mg/kg) to the AFB1 
diet was not able to prevent the negative effects of AFB1 on AWG and AFI. In 
contrast, the addition of 20 µg AFTotal/kg to the basal diet did not negatively affect 
(P > 0.05) performance of turkeys compared to control. There was no significant 
effect (P > 0.05) of dietary treatments on feed conversion (FC) or mortality. 
Effects of dietary treatments on selected serum chemistries of turkeys are 
summarized in Table 4.3. The addition of CMN alone to the basal diet did not 
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significantly affect (P > 0.05) any of the serum chemistry measurements 
(glucose, total protein, calcium and uric acid). However, turkeys fed 200 µg 
AFB1/kg diet alone or the 200 µg AFB1/kg diet supplemented with levels of 148, 
222, and 296 mg CMN/kg had reduced (P < 0.05) concentrations of glucose, total 
protein and calcium compared to control. Concentration of glucose and calcium 
were also significantly (P < 0.05) reduced in turkeys fed 20 µg AFTotal/kg 
compared to control, but total protein and uric acid concentration were similar (P 
> 0.05) to controls. Turkeys fed 200 µg AFB1/kg diet alone and AFB1 
supplemented with 74 mg CMN/kg had greater (P < 0.05) concentrations of uric 
acid compared to control.  
Effects of AFB1 on relative liver and kidney weight are summarized in 
Figure 4.1. There was no significant effect (P > 0.05) of dietary treatments on 
relative kidney weight. However, compared to control, relative liver weight was 
reduced (P < 0.05) with the addition of 200 µg AFB1/kg diet and 20 µg AFTotal/kg 
diet to the basal diet. The addition of CMN alone to the basal diet did not have 
any effect (P > 0.05) on relative liver weight compared to control. Turkeys fed 
treatment diets containing 200 µg AFB1/kg supplemented with any concentration 
of CMN (74, 148, 222, and 296 mg/kg) had significantly reduced (P < 0.05) 
relative liver weight compared to control. 
 
RNA Sequencing 
 All RNA samples used for RNA sequencing (RNA-Seq) exceeded 
minimum quality requirements based on Experion results, with Quality Indicator > 
8 on a scale of 1.0 (fully degraded) to 10.0 (intact). The differential gene list was 
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built using edgeR Bioconductor ® package comparing different treatments to 
control.  
The RNA-Seq analysis showed a total of 99,316 transcripts. Pathways of 
genes differentially expressed from RNA-Seq results of turkeys fed 200 ppb AFB1 
compared to controls are summarized in Table 4.4. Compared to controls, birds 
fed 200 µg AFB1/kg had 402 genes differentially expressed. The enrichment of 
functional clusters and important pathways (DAVID Bioinformatics Resources 
6.7®) showed that 52 genes were down regulated and were distributed into 9 
pathways, whereas 350 genes were up regulated and were distributed into 23 
pathways. Among the pathways, complement and coagulation cascade, and 
PPAR signaling pathway presented the highest number of genes down regulated 
(15 and 8, respectively), and pathways in cancer, focal adhesion, MAPK 
signaling pathway, EMC-receptor interaction, regulation of actin cytoskeleton, 
and cell cycle presented higher number of genes up regulated (46, 40, 26, 25, 
21, and 20 respectively). 
Pathways of genes differentially expressed from RNA-Seq results of 
turkeys fed 200 µg AFB1 supplemented with 74 mg CMN/kg diet compared to 
controls are summarized in Table 4.5. Compared to controls, animals fed AFB1 + 
CMN had 129 genes differentially expressed. Out of 129 genes, RNA-Seq 
analysis demonstrated that 22 were down regulated and were distributed in 6 
pathways, whereas 107 were up regulated and were distributed in 13 pathways. 
Pathways with the highest number of down regulated genes included 
complement and coagulation cascades and cysteine and methionine metabolism 
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(seven and four genes, respectively). Pathways with the highest number of up-
regulated genes included cell cycle, focal adhesion, and pathways on cancer with 
each having 13 genes up regulated. 
Pathways of genes differentially expressed from RNA-Seq results of 
turkeys fed 20 µg AFTotal/kg compared to controls are summarized in Table 4.6. 
Compared to controls, turkeys fed 20 µg AFTotal/kg only had 32 genes 
differentially expressed. The enrichment of functional clusters and important 
pathways (DAVID Bioinformatics Resources 6.7®) showed that 18 genes were 
down regulated and were distributed into five pathways, whereas 14 genes were 
up regulated and were distributed into four pathways. Pathways with higher 
number of genes up regulated are glutathione metabolism, metabolism of 
xenobiotics by cytochrome P450, and drug metabolism with four genes each, 
while ECM-receptor interaction and focal adhesion each presented four down 
regulated genes. Table 4.7 summarizes the number of genes expressed in 
similar pathways in turkeys fed 200 µg AFB1/kg, 200 µg AFB1/kg plus 74 mg 
CMN/kg diet, and 20 µg AFTotal/kg diet, compared to control. 
Table 4.8 summarizes the consistency of genes differentially expressed in 
liver samples of turkeys fed AFB1 + CMN compared to genes differentially 
expressed in turkeys fed AFB1. The number of genes differentially expressed 
was reduced comparing turkeys fed 200 µg AFB1/kg to turkeys fed 200 µg 
AFB1/kg plus 74 mg CMN/kg diet in several pathways, including complement and 
coagulation cascade, pathways in cancer, focal adhesion, ECM-receptor 
interaction, cell cycle, and glutathione metabolism. An average of 90% of genes 
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differentially expressed in turkeys fed AFB1 + CMN were also expressed in liver 
samples of turkeys fed the AFB1 diet. 
Table 4.9 summarized the difference in expression of genes in liver 
samples of turkeys fed AFB1 + CMN compared to turkeys fed AFTotal. Turkeys fed 
AFB1 with addition of CMN showed 5 genes in each pathway including 
glutathione metabolism and metabolism of xenobiotics by CYP 450 were up 
regulated. However, turkeys fed AFTotal (20 µg AFTotal – FDA recommendation 
level), showed 4 genes down regulated in the same pathways. Comparing genes 
in these pathways, 3 genes of each pathway, when turkeys were fed AFTotal diet, 
were also presented in the other treatment (AFB1 + CMN), however the 
expression of these genes were reversed. 
 Multi-dimensional scaling Plot (edgeR MDS plot) is a tool in the edgeR 
Bioconductor® software used to measure the similarities of the samples and 
plots in two dimension. The comparison of turkeys fed 200 µg AFB1/kg diet alone 
compared to control is presented in Figure 4.2. It can be observed (in dimension 
1 and dimension 2) that control (marked as “A”) and turkeys fed 200 µg AFB1/kg 
diet (marked as “C”) are well separated from each other, which demonstrates the 
difference in genes expressed between the two treatments. Also, replicates 
within each treatment are aggregated in the same dimension indicating that the 
expression of genes are consistent among the replicates of each treatment. 
 The correlation of turkeys fed 200 µg AFB1/kg diet + 74 mg CMN/kg diet 
(marked as “D”) to control is summarized in Figure 4.3. In this case, we observed 
that there is a mix of treatments in the two dimensions. This graphic indicates 
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that the presence of CMN in diets containing AFB1 was more similar to control, 
but not consistent among replicates. This could be a good indication that CMN is 
ameliorating the effects of AFB1 on gene expression. 
 Figure 4.4 summarizes the comparison between turkeys fed 20 µg 
AFTotal/kg diet (marked as “H”) and control. Replicates are distributed randomly 
around the two dimensions, indicating that samples are similar, independent of 
the treatment. This is an indication that genes expressed in birds fed 20 µg 
AFTotal/kg were similar to those fed the control diet. 
 All the above relationships can be visualized in one unique graphic (Figure 
4.5). This graphic clearly shows that control (A) and 20 µg AFTotal/kg diet (H) 
treatments are similar, whereas 200 µg AFB1/kg diet + 74 mg CMN/kg diet (D) 
treatments are closer to A, and 200 µg AFB1/kg diet (C) treatment is the most 
distant to A. 
 
 
 
 DISCUSSION 
 
Performance  
 Turkeys are an important international food commodity. The United States 
alone accounts for one-half of the turkey production in the world with 
approximately 7.30 billion pounds (live weight), with an estimated value close to 
US $ 3 billion (National Agriculture Statistics Service, USDA). Turkeys are one of 
the most sensitive species to aflatoxin (FDA – 20 µg Total AF/kg). Aflatoxin 
toxicity in turkeys may result in economic losses due to reduction in performance 
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(growth, feed efficiency), and a compromised immune system that could lead to 
diseases and death. The use of turmeric powder (TMP) has been studied as a 
natural alternative for reducing the toxic effects of aflatoxin in poultry. Turmeric is 
a spice made from the rhizomes of a tropical Asian plant. It is a common spice in 
curries used in Asian and Middle Eastern cuisine. Turmeric powder (which 
contains curcumin - CMN) has been used as an antioxidant supplement in AFB1 
contaminated diets fed to poultry and swine. In the present study, birds fed 200 
µg AFB1/kg diet had decreased performance compared to control birds. The 
addition of incremental levels (74, 148, 222, and 296 mg/kg) of CMN to the AFB1 
diet was not able to prevent the negative impact on performance caused by 
AFB1. On the other hand, turkeys fed the FDA action’s level of AF (20 µg 
AFBTotal/kg diet) had similar performance results compared to controls. Yarru et 
al. (2009b) reported that broiler chicks fed 1 mg AFB1/kg and supplemented with 
0.5% TMP (74 mg/ kg of total curcuminoids) had numerically increased feed 
intake and significantly improved BWG compared to chicks fed the diet 
containing AFB1 alone. Similar results were reported by Gowda et al. (2008) who 
showed a significant improvement in weight gain and a numeric increase in feed 
intake when birds were fed diets containing 1.0 mg AFB1/kg supplemented with 
0.5% TMP (74 mg/ kg of total curcuminoids) compared to birds fed 1.0 mg 
AFB1/kg diet. According to the authors, these results suggest antioxidant 
protection by TMP. In the present study, the supplementation of the highest level 
of CMN (296 mg CMN/kg diet) alone did not have any impact on performance of 
turkeys, but CMN was not able to prevent the negative effects of 200 µg AFB1/kg 
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diet. This inability of CMN to ameliorate the effects of AFB1 in turkey poults 
suggest that turkeys are more efficient at converting AFB1 to its carcinogenic 
form (AFB1 – 8,9 Epoxide) and less efficient in detoxifying AFB1 compared to 
broilers, where CMN was able to reduce the effects of AFB1 (Yarru et al., 2009a). 
Supplementation of CMN at higher levels than the level used in the present study 
(above 296 mg CMN/kg diet) could be tested in future studies to determine the 
ideal concentration of CMN in ameliorating the toxic effects of AFB1 in turkeys, 
and also to determine if higher levels of CMN alone could have a negative impact 
on performance of turkeys. 
 
RNA-Seq analysis 
 It is well documented that the carcinogenic form of aflatoxin B1 (AFB1 – 8,9 
Epoxide) causes damage to DNA (Bedard and Massey, 2006). The RNA-seq 
analysis is a very useful tool to understand the mechanisms and pathways of 
AFB1 toxicity by mapping genes that can be differentially expressed by the toxic 
effects of AFB1. In the present study, we observed the differential expression of 
genes related to several pathways. In turkeys fed 200 µg AFB1/kg diet, when 
compared to control, several genes related to pathways such as complement and 
coagulation cascade and the PPAR signaling pathway were down regulated, 
whereas genes related to pathways in cancer, focal adhesion, MAPK signaling 
pathways and ECM-receptor interaction were up regulated (Table 4.4). The 
addition of CMN to the AFB1 diet presented genes expressed in similar pathways 
(as found in turkeys fed AFB1 alone), but the number of gene expressed was 
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significantly reduced (Table 4.5). This could be an indication that CMN was able 
to ameliorate the negative effects of AFB1 on gene expression.  
When turkeys were fed the FDA’s action level for AF (20 µg AFTotal/kg), 
there was not a big impact on hepatic gene expression. However, there was 
down regulation of genes in important pathways related to the AF detoxification 
process, such as glutathione metabolism (four genes) and metabolism of 
xenobiotics by cytochrome P450 (four genes). These results indicate that even if 
FDA action’s level does not have an impact on growth performance, it does affect 
the hepatic expression of some genes. 
 
Complement and coagulation cascade 
 The complement and coagulation cascade pathway is illustrated in Figure 
4.6. The complement system and coagulation are two pathways readily activated 
after injuries. The complement system is a major component of the innate 
immunity system while the coagulation system is a major player in hemostasis 
(Amara et al., 2008). A cascade effect could be triggered by the expression of 
genes affected by AFB1. Genes involved in blood coagulation (such as 
coagulation factor IX, X, and XIII) and complement metabolism (such as 
complement factor H, complement component 6 and 8) were down regulated in 
birds fed diets containing 200 µg AFB1/kg diet alone and 200 µg AFB1/kg diet + 
74 mg CMN/kg diet. In birds fed 20 µg AFTotal/kg diet, there was no differential 
expression of genes related to this pathway. Depressed expression of 
coagulation factor X was reported by Doerr and Hamilton (1981) when broilers 
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were fed 10 µg/g AF for 3 weeks. Yarru et al. (2009a) observed down regulation 
of genes involved in blood coagulation (coagulation factor IX and X) in broilers 
fed 2 mg AFB1/kg. Obasi et al. (1994) reported an increase of bleeding time in 
chicks treated with single oral doses of 50 µg AFB1/kg body weight. Blood 
coagulation time was statistically increased after intraperitoneal (I.P.) 
administration of AFB1 (58 µg AFB1/kg body weight) in ducks and chickens 
(Bababunmi and Bassir, 1982).  Asuzu et al. (1988) reported increased whole 
blood clotting time in albino rats administrated with 25 µg AFB1/kg. Clark et al. 
(1986) reported an increase in time of prothrombin and thromboplamic activities, 
and a decrease of fibrinogen, Factor IX, VIII, and activities in rabbits fed 50µg 
AFB1/kg diet. The authors concluded that the coagulation factor deficiencies 
were attributed to a decrease in factor synthesis due to hepatic insufficiency. 
Down regulation of genes in coagulation pathways could impair blood clotting, 
leading to hemorrhages in turkeys fed AFB1. Blood clots in carcasses caused by 
decreased expression of coagulation factors and the complement system could 
also cause economic losses due to downgrading or condemnation of carcasses. 
The number of genes differentially expressed in turkeys fed AFB1 + CMN was 
reduced compared to turkeys fed the diet containing AFB1 (15 to 7). All 7 genes 
differentially expressed in turkeys fed AFB1 + CMN were also differentially 
expressed in turkeys fed diets containing AFB1. The lower number of genes 
expressed in this pathway could be attributed to the protective effect of 
curcuminoids of hepatic cell against the negative effects of AFB1. 
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Pathways in cancer 
 Pathways in cancer is illustrated in Figure 4.7. Aflatoxin B1 is known to 
cause liver cancer, playing a role in several pathways involved in cancer. Several 
genes associated with pathways in cancer (Apoptosis regulator Bcl-X, bcl-2-like 
protein 1, SMAD family member 4, cyclin A1, cyclin D1, laminin alpha 2, jun 
oncogene) were up regulated in turkeys fed diets containing 200 µg AFB1/kg diet 
alone. Up regulation of these genes could contribute to increase cell proliferation 
rates in turkeys fed 200 µg AFB1/kg diet. In birds fed 20 µg AFTotal/kg diet, there 
was no differential expression of genes related to this pathway. 
The inclusion of 74 mg CMN/kg to the diet containing 200 µg AFB1/kg diet 
reduced the number of genes up regulated from 46 to 13, compared to turkeys 
fed the 200 µg AFB1/kg diet alone. Of the 13 genes differentially expressed in 
birds fed AFB1 + CMN, 12 genes (except for laminin, beta 3) were also present in 
birds fed AFB1 alone (92% similarity). This suggests that the presence of 
curcumin as an antioxidant reduced the negative effects of AFB1 on genes 
related to this pathway. Studies suggest that curcumin may have antitumor, 
antioxidant, and anti-inflammatory properties (Altaf et al., 2012). According to 
Kuttan et al. (2007) curcumin induced cell cycle arrest by reducing the 
expression of cyclin D1, cdk1, cdc-25, allowing cells to survive, thus providing a 
way for the apoptotic machinery to act.  
Yarru (2008) stated that broilers do not generally live long enough to 
develop cancer, being raised from 6 to 7 weeks. However turkeys are generally 
raised for 18 to 22 weeks which could increase the probability of cancer 
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development. Moreover, diseases associated with the consumption of AFB1 
could decrease growth performance and decrease resistance to microbial 
pathogens, leading to increased mortality. According to Rawal et al. (2010) the 
extreme sensitivity of turkeys to AFB1 is associated with efficient hepatic 
cytochrome P450-mediated bioactivation of aflatoxin and deficient aflatoxin 
detoxification by glutathione S-transferases (GST).  
 
Focal adhesion 
 The focal adhesion pathway is illustrated in Figure 4.8. Focal adhesions 
serve as the chemical linkage to the extracellular matrix (ECM), and as a 
biochemical signaling hub to concentrate and direct numerous signaling proteins 
to sites of integrin binding and clustering (Chen et al., 2003).The dynamic 
assembly and disassembly of focal adhesions plays a role in cell migration 
(Huttenlocher et al., 1997). Cell migration is important for the development and 
maintenance of multicellular organism, acting in wound healing and immune 
response. An error in this pathway could enhance the probability of tumor 
formation. Genes associated with focal adhesion (such as Ras protein-specific 
guanine nucleotide-releasing factor 1, cyclin D1, collage typeIII alpha 1, platelet-
derived growth factor beta polypeptide, jun oncogene) were up regulated in 
turkeys fed diets containing AFB1 alone. Up regulation of the genes described 
above could be an indication of the increased permeability of reactive oxygen 
species (ROS) into the cell. In birds fed 20 µg AFTotal/kg diet, the number of 
genes differentially expressed in this pathway was reduced to four genes, 
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indicating that even low levels of AFs can induce the up regulation of genes in 
the focal adhesion pathway. 
However, the inclusion of CMN in the diet containing AFB1 reduced the 
number of genes up regulated from 40 to 13, compared to turkeys fed the AFB1 
alone. Ten of 13 genes differentially expressed in turkeys fed AFB1 + CMN 
(except for laminin, beta 3; myosin, light chain 10, regulatory; and tenascin XB) 
were also differentially expressed in turkeys fed AFB1 alone (76% similarity). The 
decreased number of genes expressed in pathway when turkeys were fed 200 
µg AFB1/kg diet supplemented with 74 mg CMN/kg diet could be an indication 
that curcumin as an antioxidant (reducing the concentration of ROS) reduced the 
negative effects of AFB1 in genes related to this pathway.  
 
ECM-receptor interaction  
 The ECM-receptor interaction pathway is illustrated in Figure 4.9. The 
extracellular matrix (ECM) consists of a complex mixture of structural and 
functional macromolecules and serves an important role in tissue and organ 
morphogenesis, and in the maintenance of cell and tissue structure and function. 
Genes associated to EMC-receptor interaction (such as collagen type I, III, IV, V, 
and VI, heparin sulfate proteoglycan2, hyaluran-mediated motility receptor, 
laminin beta 1 to 7, and gamma 1 and 2, thrombospodin, reelin, and syndecan 1) 
were up regulated in  turkeys fed 200 µg AFB1/kg diet alone. In birds fed 20 µg 
AFTotal/kg diet, the number of genes differentially expressed in this pathway was 
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reduced to four genes, indicating that even low levels of AFs can induce the up 
regulation of genes in the ECM-receptor interaction pathway. 
However, the inclusion of 74 mg CMN/kg diet in the diet containing 200 µg 
AFB1/kg diet reduced the number of genes up regulated from 25 to 11, compared 
to turkeys fed the AFB1 alone Eight of the 11 genes up regulated in turkeys fed 
AFB1 + CMN (except for laminin, beta 3; collagen, type I, alpha 3; and tenascin 
XB) were also up regulated in turkeys fed AFB1 alone. (72% similarity).  The 
reduction in the number of genes up regulated when supplemented with CMN 
could be due the antioxidant protection by curcumin, reducing ROS, and 
protecting the cell from oxidative effects. According to Mathivadhani et al. (2007) 
one of the main functions of ECM, in the tumour microenvironment, is to be a 
barrier against tumour invasion. Up regulation of genes associated with ECM-
receptor interaction is consistent with this role because the presence of aflatoxin 
could increase the probability of cancer.  
 
Regulation of actin cytoskeleton 
Regulation of actin cytoskeleton is illustrated in Figure 4.10. Actin is the 
thinnest filament of the cytoskeleton. The cytoskeleton of the cell is responsible 
for maintaining cell shape, cell protection, and cellular motion. The cytoskeleton 
also plays an important role in cell division and intracellular transport. Genes 
associated with regulation of actin cytoskeleton (such as actin β, actin α1, 
fibroblast growth factor 10, integrin α3, 4, 6, and 7, myosin heavy chain 9 (non-
muscle), scinderin, and vinculin) were up regulated in turkeys fed 200 µg 
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AFB1/kg diet alone. Compared to controls, birds fed 200 µg AFB1/kg diet 
supplementation with 74 µg CMN/ kg diet, and birds fed 20 µg AFBTotal/kg diet did 
not show differential expression of genes in this pathway. These results could be 
an indication that the supplementation of CMN at its lowest level (74 mg CMN/ 
kg) was able to preserve cells from the necrotic process, preventing the up 
regulation of selected genes in cellular structure repair. Koo et al. (1987) reported 
that the presence of aflatoxin B1 in the organism may cause lethal effects by 
different biological mechanisms that are associated with remarkably distinct 
prelethal cytoskeletal responses. Ellimger-Ziegelbauer et al (2004) reported up 
regulation of genes encoding proteins that function in cytoskeleton organization 
in rats fed AF. The authors concluded that the necrotic processes observed in 
their study could be caused by changed expression of genes in the cytoskeleton 
regulation. Yarru et al. (2009a) reported up and down regulation of several genes 
related to cell skeletal structure pathways. Findings in the current study may be a 
result of cells that are in the process of preventing of cell necrosis and/or 
regeneration of surrounding cells, and are consistent with previous reports by 
Ellimger-Ziegelbauer et al (2004) and Yarru et al. (2009a). 
 
Cell cycle 
Cell cycle metabolism is illustrated in Figure 4.11. Aflatoxin B1 is readily 
transported across the plasma membrane and interacts with nucleic acids and 
protein causing cellular damage by covalent modification of nucleic acids 
(Ricordy et al., 2002; Raj et al., 1998). Aflatoxin B1 exposure causes alteration of 
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several specific cellular activities; among these, impairment of the cell cycle 
progression mechanism appears particularly relevant, considering the 
carcinogenic action of the toxin (Ricordy et al., 2005). Genes associated with the 
cell cycle (such as cyclin A1, B3, and D1, SMAD family member 4, 
minichromosome maintenance complex component 2, 5, and 7, pituitary tumor-
transforming, polo-like kinase 1, transforming growth factor β1 and β3, cell 
division cycle 2, G1 to S and G2 to M) were up regulated in turkeys fed diets 
containing 200 µg AFB1/kg diet alone. In birds fed 20 µg AFTotal/kg diet, there was 
no differential expression of genes related to this pathway. Yarru et al. (2009a) 
reported up regulation of genes related to cell proliferation pathways in chicks fed 
2 mg AFB1/kg. Cyclins are proteins that interact with tumor suppressor protein 
Retinoblastome protein (Rp). Up regulation of these genes could alter cell cycle 
progression and contribute to tumorigenesis (NCBI, 2013). 
Up regulation of the above mentioned genes suggest that AFB1 can cause 
alteration in the cell cycle, causing cellular damage. However, the inclusion of 
CMN in the diet containing AFB1 reduced the number of genes up regulated from 
20 to 13, compared to turkeys fed the AFB1 alone All the 13 genes differentially 
expressed in pigs fed AFB1 + CMN were also differentially expressed in turkeys 
fed diets containing AFB1. Curcumin has been shown to inhibit carcinogenesis in 
several tissues (Chuang et al., 2000). The inhibition of tumor formation by 
curcumin has been attributed to its anti-initiation (ability to inhibit the formation of 
DNA damage) and anti-promotion (mediated through anti-proliferation or anti-
apoptosis promotion of the initiated cells) effects in the cell (Shalini and Srinivas, 
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1987; Chen and Huang, 1998; Sikora et al., 1997). The decreased number of 
genes up regulated with the addition of CMN is consistent with the role of 
curcumin in cell protection. 
 
Metabolism of xenobiotics by CYP450 and Glutathione metabolism 
 Glutathione metabolism is illustrated in Figure 4.12, and Metabolism of 
xenobiotics is illustrated in Figure 4.13. It is known that AFB1 is converted to its 
carcinogenic form (AFB1-8,9-epoxide (AFBO)) by cytochrome P450 (CYP450s) 
enzymes. Xenobiotics are chemicals found in the organism that it does not 
normally produce or are expected to be present. The body removes these 
compounds by the metabolism of xenobiotics, which consist of the activation and 
the excretion of the xenobiotics via urine, feces, breath and sweat. The highest 
concentration of CYP450s involved in xenobiotic biotransformation is found in the 
endoplasmic reticulum of hepatocytes but CYP450s are present in virtually every 
tissue (Diaz and Murcia, 2011). Glutathione metabolism is important for the 
process of detoxification and excretion of AFB1 from the organism. Phase I 
metabolites (AFB1-8,9-epoxide) may undergo phase II metabolism involving the 
enzyme glutathione S-transferase (GST), which will produce conjugates of AFB1 
and glutathione, which is the principal detoxification pathway of activated AFB1, 
reducing and preventing the carcinogenic effects of AFB1. The resulting 
conjugates are readily excreted via bile into the intestinal tract and excreted in 
the excreta. 
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Genes associated with both pathways, glutathione metabolism and 
metabolism of xenobiotics by cytochrome P450, (glucose-6-phosphate 
dehydrogenase, glutathione S-transferase alpha (GSTα) 1, glutathione S-
transferase alpha 2, glutathione S-transferase alpha 4, glutathione S-transferase 
alpha 5, ornithine decarboxylase 1, ribonucleotide reductase M1, and 
ribonucleotide reductase M2 polypeptide) were up regulated in birds fed 200 µg 
AFB1/kg diet alone (eight genes) and 200 µg AFB1/kg diet plus 74 µg CMN/ kg 
diet (five genes). The reduction in the number of up regulated genes in birds fed 
200 µg AFB1/kg and supplemented with 74 µg CMN/ kg diet, could be an 
indication that the presence of curcumin, which has antioxidant properties, is 
alleviating the oxidative stress caused by the presence of AFB1.  In contrast, 
birds fed 20 µg AFTotal/kg diet had down regulation of four genes (glutathione S-
transferase α1, α2, α5 and mu4). Down regulation of GSTα in broilers fed 1.0 mg 
AFB1/kg diet was observed by Yarru et al. (2009b). According to the authors, the 
decreased hepatic gene expression of GSTα could limit the ability of the hepatic 
tissue to conjugate reactive metabolites. Yarru et al. (2009b) also reported that 
the supplementation of 74 mg CMN/kg to diets containing AFB1 was able to 
alleviate the expression of GSTα in broilers. Beers et al. (1992) reported increase 
hepatic and renal glutathione in male chickens fed 2 mg AFB1/kg. Valdivia et al. 
(2001) reported an increased in 48% of GST when broilers were fed 3 mg 
AFB1/kg feed for 21 d.  
Even with the similarity in performance when turkeys were fed 20 µg 
AFTotal/kg diet compared to controls, down regulation of genes related to 
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glutathione metabolism and metabolism of xenobiotics by cytochrome P450 
could be an indication of the toxic effects of AFB1 in reducing the ability of 
hepatic enzymes to conjugate metabolites allowing them to be eliminated from 
the organism. In short term exposure (3 weeks), the presence of AFTotal did not 
show negative effects on performance. However exposure to longer periods 
could have an impact on animal performance and health.  
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SUMMARY AND CONCLUSIONS 
It is very important to understand the mechanism of action of aflatoxin B1 
and, consequently genes associated with important pathways. Current findings 
suggest the presence of AFB1 in a turkey diet has a negative impact on 
performance (body weight gain and feed intake), and liver weight, and adverse 
effects on serum glucose, total protein, calcium concentration, and uric acid. 
Exposure of turkey poults to 200 µg AFB1/kg resulted in physiological responses 
associated with altered gene expression in the liver of turkeys. The exposure of 
turkey poults to 20 µg total AF/kg did not affect performance but caused 
alteration in serum glucose and calcium, and altered expression of genes in the 
liver.  
Results of the present experiment indicate that inclusion of curcumin alone 
did not have a negative impact on any response variable measured.  However, 
curcumin, regardless of inclusion rate, was not effective in ameliorating the toxic 
effects of 200 µg AFB1/kg diet on growth performance of female poults fed 
dietary treatments from hatch to day 21.  Results also indicate that 20 µg/kg of 
total AF (AFB1, AFB2, AFG1, and, AFG2), the FDA’s action level for AF in poultry 
diets, does not negatively affect growth performance by changes in hepatic gene 
expression.  
Moreover, the highest numbers of differentially expressed genes were 
found when birds were fed 200 µg AFB1/ kg diet alone compared to control, 
which was expected due to the administration of such a high dose of AFB1. 
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Also, results of this study suggested that the administration of the highest 
level (296 mg CMN /kg of diet) of curcumin supplied from turmeric powder was 
not able to ameliorate the adverse effects of 200 µg AFB1/kg diet fed to turkey, 
resulting in physiological responses (reduced average weight gain, feed intake, 
and serum glucose, total protein and calcium concentration). However, the 
presence of curcumin was able to alleviate changes in hepatic gene expression. 
Higher levels of curcumin should be tested to determine its efficacy against the 
negative effects of AFB1 fed to turkey poults. 
The FDA’s action level for AF in immature animals caused the lowest 
numbers of differentially expressed genes, suggesting that even at low levels, 
aflatoxin may cause alteration in the expression of specific genes which could 
cause, in long term exposure, negative effects on performance. 
 In our study we hypothesized that 200 µg aflatoxin B1 per kilogram 
in the diet would cause changes in the expression of genes in turkey poults, 
which was confirmed. We also hypothesized that supplementation of curcumin 
(CMN) up to 296 milligrams per kilograms would ameliorate the toxic effects of 
aflatoxin B1 in turkey poults. We observed that CMN was not able to reduce the 
negative effects of aflatoxin B1 on performance of turkeys, however CMN was 
able to reduce the number of genes differentially expressed in several pathways, 
confirming partially our hypothesis. For last, we hypothesized that the 
supplementation of aflatoxin B1 at the Food and Drug Administration (FDA) 
regulatory level (20 µg AFTotal) would not have negative effects on growth 
performance or cause changes in hepatic gene expression in turkey poults. Our 
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hypothesis was also partially confirmed since we did not observe changes on 
performance compared to control, but we observed changes in gene expression 
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Table 4.1 – Ingredient and nutrient composition of diets (as-fed1) 
Item % of Diet 
Ingredient  
   Corn, Yellow dent 43.07 
   Soybean Meal, 48% CP 50.48 
   Dicalcium phosphate, 21% P 2.43 
   Corn oil 1.64 
   Limestone 1.27 
   Vitamin Premix2 0.50 
   Salt, NaCl 0.39 
   L-Lysine HCL 0.012 
   DL-Methionine 0.012 
1Diet formulated to contain: 28% CP, 1.2% Ca, 0.6% available P, and 1.6% total 
lysine. 
2Vitamin/Mineral Premix supplied per kilogram of diet: Zn, 100 mg (ZnSO4); Fe, 
50 mg (FeSO4H2O); Cu, 16.5 mg (CuSO4H2O); Mn, 33 mg (MnSO4); I, 0.3 mg Ca 
(IO3); and Se, 0.3 mg (NaSeO3), retinyl acetate, 11,000 IU; cholecalciferol, 1,100 
IU; DL-α-tocophereryl acetate, 44.1 IU; menadione Na dimethylpyrimidinol 
bisulfate, 4.0 mg; vitamin B12, 30.3 μg; riboflavin, 8.3 mg; D-Ca-pantothenate, 
28.1 mg; nicotinamide, 33.1 mg; choline chloride, 551.3 mg; D-biotin, 0.22 mg; 
and folic acid, 1.65 mg. 
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Table 4.4 – Pathways represented by genes identified as differentially expressed 
from RNA-Seq results of turkeys fed 200 µg AFB1/kg compared to control (A total 
of 402 genes differentially expressed, of which 350 genes were up regulated and 
52 genes were down regulated).  
Down regulated 
Pathways  Genes P-value 
Complement and coagulation cascades 15 < 0.001 
PPAR signaling pathway 8 < 0.001 
Valine, leucine and isoleucine degradation 5 0.018 
Arachidonic acid metabolism 5 0.040 
Linoleic acid metabolism 4 0.026 
Glycine, serine and threonine metabolism 4 0.034 
Cysteine and methionine metabolism 4 0.043 
Fatty acid metabolism 4 0.006 
Synthesis and degradation of ketone bodies 3 0.017 
Up regulated 
Pathways in cancer 46 < 0.001 
Focal adhesion 40 < 0.001 
MAPK signaling pathway 26 0.012 
ECM-receptor interaction 25 < 0.001 
Regulation of actin cytoskeleton 21 0.024 
Cell cycle 20 < 0.001 
Colorectal cancer 16 < 0.001 
Small cell lung cancer 14 0.001 
Hypertrophic cardiomyopathy (HCM) 14 0.001 
Dilated cardiomyopathy 14 0.002 
TGF-beta signaling pathway 13 0.004 
Chronic myeloid leukemia 12 0.004 
Adherens junction 11 0.013 
Progesterone-mediated oocyte maturation 11 0.027 
Basal cell carcinoma 10 0.004 
Renal cell carcinoma 9 0.049 
DNA replication 8 0.004 
Glutathione metabolism 8 0.024 
Hedgehog signaling pathway 8 0.042 
Pathogenic Escherichia coli infection 8 0.046 
Endometrial cancer 7 0.080 
Thyroid cancer 5 0.085 
Terpenoid backbone biosynthesis 4 0.053 
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Table 4.5 – Pathways represented by genes identified as differentially expressed 
from RNA-Seq results of turkeys fed 200 µg AFB1/kg plus 74 mg CMN/kg 
compared to control (A total of 129 genes differentially expressed, of which 109 
genes were up regulated and 22 genes were down regulated).  
Down regulated 
Pathways Genes P-value 
Complement and coagulation cascades 7 < 0.001 
Cysteine and methionine metabolism 4 0.004 
Phenylalanine metabolism 3 0.020 
Linoleic acid metabolism 3 0.032 
Glycine, serine and threonine metabolism 3 0.038 
Phenylalanine, tyrosine and tryptophan biosynthesis 2 0.049 
Up regulated 
Cell cycle 13 < 0.001 
Focal adhesion 13 0.002 
Pathways in cancer 13 0.049 
ECM-receptor interaction 11 < 0.001 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 10 < 0.001 
Oocyte meiosis 8 0.012 
Small cell lung cancer 7 0.012 
Progesterone-mediated oocyte maturation 7 0.013 
Drug metabolism 6 0.013 
Alanine, aspartate and glutamate metabolism 5 0.005 
Glutathione metabolism 5 0.026 
Metabolism of xenobiotics by cytochrome P450 5 0.047 
DNA replication 4 0.048 
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Table 4.6 – Pathways represented by genes identified as differentially expressed 
from RNA-Seq results of turkeys fed 20 µg/kg of total aflatoxin compared to 
control (A total of 32 genes differentially expressed, of which 14 genes were up 
regulated and 18 genes were down regulated). 
Down regulated 
Pathways Genes P-value 
Glutathione metabolism 4 0.002 
Metabolism of xenobiotics by cytochrome P450 4 0.003 
Drug metabolism 4 0.003 
Basal cell carcinoma 3 0.029 
Hedgehog signaling pathway 3 0.03 
Up regulated 
ECM-receptor interaction 4 0.006 
Focal adhesion 4 0.036 
Adipocytokine signaling pathway 3 0.036 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 3 0.046 
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 Table 4.7 – Pathways represented by the genes identified differentially 
expressed from RNA-seq analysis of turkeys fed AFB1, AFB1 + CMN, and AFTotal. 
Pathways AF AF+CMN AF total 
Down regulated 
Complement and coagulation cascades 15 7 - 
Linoleic acid metabolism 4 3 - 
Glycine, serine and threonine metabolism 4 3 - 
Cysteine and methionine metabolism 4 4 - 
Up regulated 
Pathways in cancer 46 13 - 
Focal adhesion 40 13 4 
ECM-receptor interaction 25 11 4 
Regulation of actin cytoskeleton 21 - - 
Cell cycle 20 13 - 
Basal cell carcinoma 10 - 3 down 
DNA replication 8 4 - 
Glutathione metabolism 8 5 4 down 
Hedgehog signaling pathway 8 - 3 down 
Metabolism of xenobiotics by CYP450 - 5 4 down 
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Table 4.8 – Consistency of genes differentially expressed in liver samples of 
turkeys fed AFB1 + CMN compared to genes differentially expressed in turkeys 
fed AFB1. 
Pathways AFB1 AFB1+CMN Similar genes1 
Down regulated 
Complement & coagulation cascade2 15 7 7 
Up regulated 
Pathways in cancer3 46 13 12 
Focal adhesion4 40 13 10 
ECM- receptor interaction5 25 11 8 
Cell Cycle6 20 13 13 
Glutathione metabolism7 8 5 5 
1Similar genes means that the number of genes differentially expressed between 
pigs fed AFB1 and AFB1 + CMN are in common within each pathway. 
2In complement and coagulation cascade, the addition of CMN in diets containing 
AFB1 reduced the number of genes differentially expressed from 15 to 7. All 7 
genes were consistent in both treatments. 
3In Pathways in cancer the addition of CMN in diets containing AFB1 reduced the 
number of genes differentially expressed from 46 to 13, of which 12 genes were 
consistent in both treatments (92% similar). 
4In Focal adhesion the addition of CMN in diets containing AFB1 reduced the 
number of genes differentially expressed from 40 to 13, of which 10 genes were 
consistent in both treatments (76% similar). 
5In ECM-receptor interaction the addition of CMN in diets containing AFB1 
reduced the number of genes differentially expressed from 25 to 11, of which 8 
genes were consistent in both treatments (72% similar). 
6 In cell cycle, the addition of CMN in diets containing AFB1 reduced the number 
of genes differentially expressed from 20 to 13. All 13 genes were consistent in 
both treatments. 
7 In glutathione metabolism, the addition of CMN in diets containing AFB1 
reduced the number of genes differentially expressed from 8 to 5. All 5 genes 
were consistent in both treatments. 
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Table 4.9 – Difference of expression of genes in liver samples of turkeys fed 
AFB1 + CMN compared to turkeys fed AFTotal. 
Pathways AFB1 
+CMN 
AF  
Total 
Similar 
genes1 
Glutathione metabolism2 5 (up) 4 (down) 3 
Metabolism of xenobiotics by CYP 4503 5 (up) 4 (down) 3 
1Similar genes means that the number of genes differentially expressed between 
pigs fed AFB1 and AFB1 + CMN are in common within each pathway. 
2-3In glutathione metabolism and metabolism of xenobiotics by CYP 450, the 
addition of CMN in diets containing AFB1 fed to turkeys showed up regulation of 
5 genes related to these pathways, while turkeys fed AFTotal showed down 
regulation of 4 genes, of which 3 genes were similar in both treatments, but 
responded in a different way. 
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Figure 4.6 – Expression of genes in complement and coagulation cascade. 
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Figure 4.9 – Expression of genes in ECM-receptor interaction 
 
 129 
 
  
F
ig
u
re
 4
.1
0
 -
 E
x
p
re
s
s
io
n
 o
f 
g
e
n
e
s
 i
n
 R
e
g
u
la
ti
o
n
 o
f 
a
c
ti
n
 c
y
to
s
k
e
le
to
n
 p
a
th
w
a
y
 
 130 
 
  F
ig
u
re
 4
.1
1
 -
 E
x
p
re
s
s
io
n
 o
f 
g
e
n
e
s
 i
n
 C
e
ll 
c
y
c
le
 p
a
th
w
a
y
 
 131 
 
 
Figure 4.12 – Expression of genes in glutathione metabolism 
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Figure 4.13 – Expression of genes in metabolism of xenobiotics by CYP 450  
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CHAPTER V 
 
EFFECTS OF AFLATOXIN B1 ON HEPATIC GENE EXPRESSION: PIGS VS. 
TURKEYS – A COMPARISON 
 
 In the two studies previously presented, several genes and pathways were 
affected by the inclusion of AFB1 in the diets of pigs and turkeys. Pigs fed 1.0 mg 
AFB1/kg showed 269 differentially expressed compared to control, and pigs fed 
1.0 mg AFB1/kg + 100 mg CMN showed 370 genes differentially expressed 
compared to control. In contrast, turkeys fed 200 µg AFB1/kg showed 402 
differentially expressed compared to control, and turkeys fed 200 µg AFB1/kg + 
74 mg CMN showed 129 genes differentially expressed compared to control. 
There are some similar pathways comparing the two species when fed diets 
containing AFB1 including lipid metabolism, PPAR signaling pathway, drug 
metabolism, metabolism of xenobiotics by cytochrome P450, glycine and 
threonine metabolism. There are also some similar pathways when both species 
were fed diets containing AFB1 + CMN including cell cycle (cellular process), 
nucleic acid binding, drug metabolism, metabolism of xenobiotics by cytochrome 
P450, active transmembrane transporter activity, threonine protease, and 
pathways in cancer. However, comparing genes differentially expressed in both 
species, only two genes were similar, which are ATP9A (ATPase, class II, type 9) 
and UCHL1 (Ubiquitin carboxyl-terminal esterase L1). 
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 Differences between the two species could be explained by some 
arguments: 
Different species: 
 Poultry and swine are two different species and their sensitivity to aflatoxin 
is also different. Several mechanisms, during AFB1 intoxication could be involved 
and different species respond in different ways. Turkeys are the most sensitive 
species related to AFB1. It is still unclear why turkey are more sensitive than 
other species (including other poultry species), but it is known that turkeys are 
more efficient in converting AFB1 to its carcinogenic form (AFB1-8,9-epoxide), 
and less efficient in the detoxification process (conjugating AFB1-glutathione, 
producing a hydrophilic form which will be excreted). The greater sensitivity of 
turkeys to AFB1 could involve different mechanisms, and changes in specific 
genes in pigs compared to turkeys.  
Gene expression analysis 
 In the studies previously presented, two different techniques were used to 
determine changes in hepatic gene expression, including microarray analysis 
(pigs) and RNA-seq (turkeys). Microarray analysis is less accurate than RNA-
seq, and can produce a large number of false positive data (due to errors in the 
hybridization process), decreasing the credibility of the results. Moreover, 
microarray analysis needs a reference sequence for the gene/genome to be 
assayed. In other words, if the reference sequence is not present, it is impossible 
to detect changes in expression of a specific gene of interest. 
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 Summarizing, both species, turkey and pigs, responded similarly on 
performance when AFB1 and curcuminoids were administrated in the diet. 
Several pathways also were similar between the two species, but only two genes 
differentially expressed were similar. This could be a result of how animals of 
different species respond to AFB1 toxication, activating similar pathways but 
increasing the expression of different genes within pathways. 
 More research is necessary to verify and compare changes in gene 
expression between the two species. Also, the use of the same technique (either 
microarray or RNA-seq) to analyze changes in gene expression would increase 
the probability of more accurate results, making the comparison of genes 
between different species more reliable.  
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CHAPTER VI 
 
SUMMARY AND OVERALL CONCLUSIONS 
 
 Aflatoxin B1 (AFB1) is a carcinogenic toxin affecting liver (hepatotoxic) 
function and health. Depending on time of exposure and concentration, AFB1 
may cause changes in the expression of genes, decrease performance of 
animals and, consequently, have a negative economic impact by downgrading 
carcass yield and increasing mortality. 
 Curcuminoids are supplied in Turmeric (Curcuma longa) powder, a spice 
used in the Indian cuisine. Curcuminoids are potent antioxidants, and have been 
shown to inhibit the biotransformation of AFB1 to its active epoxide (AFB1-8,9-
epoxide), which is carcinogenic. Curcuminoids have been shown in several 
studies to have protective effects against the negative effects of AFB1 in poultry 
and swine species. However, in the studies presented previously, the 
supplementation of curcuminoids in diets containing AFB1 was effective in 
alleviating the negative effects of AFB1 on performance of turkeys and pigs. 
However, the addition of curcuminoids in diets containing AFB1 was able to 
reduce the number of genes differentially expressed, alleviating the impact of 
AFB1 at the gene level. 
In the present study, we were able to identify several metabolic pathways 
affected by aflatoxin B1.These results could be used as a tool for researchers in 
development of new approaches to reduce the negative effects of AFB1. These 
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approaches could be nutritional (use of antioxidants and adsorbents), and also 
pharmaceutical (developing new drugs that could reduce or block some 
pathways in response to AFB1).  
Moreover, the findings of these studies could help researchers to 
understand some pathways and, maybe in the near future, select animals 
genetically more resistant, and more efficient in the detoxification process of 
AFB1. 
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